{
  "metadata": {
    "config": {
      "backend": {
        "_target_": "cotlab.backends.VLLMBackend",
        "tensor_parallel_size": 1,
        "dtype": "bfloat16",
        "trust_remote_code": true,
        "max_model_len": 4096
      },
      "model": {
        "name": "google/medgemma-27b-text-it",
        "variant": "27b",
        "max_new_tokens": 1024,
        "temperature": 0.7,
        "top_p": 0.9,
        "safe_name": "medgemma_27b"
      },
      "prompt": {
        "_target_": "cotlab.prompts.OncologyPromptStrategy",
        "name": "oncology",
        "contrarian": false,
        "few_shot": false,
        "answer_first": true,
        "output_format": "json"
      },
      "dataset": {
        "_target_": "cotlab.datasets.OncologyDataset",
        "name": "oncology",
        "path": "data/oncology.json"
      },
      "experiment": {
        "_target_": "cotlab.experiments.RadiologyExperiment",
        "name": "radiology",
        "description": "Pathological fracture detection from radiology reports",
        "num_samples": -1
      },
      "seed": 42,
      "verbose": true,
      "dry_run": false
    },
    "start_time": "2026-01-10T20:10:08.745335"
  },
  "experiment": "radiology",
  "model": "google/medgemma-27b-text-it",
  "prompt_strategy": "oncology",
  "metrics": {
    "correct": 50,
    "incorrect": 50,
    "true_positives": 0,
    "true_negatives": 50,
    "false_positives": 0,
    "false_negatives": 50,
    "parse_errors": 0,
    "accuracy": 0.5,
    "parse_error_rate": 0.0,
    "precision": 0,
    "recall": 0.0,
    "f1": 0
  },
  "raw_outputs": [
    {
      "sample_idx": 0,
      "input": "02/01/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Resolved febrile illness. Blood counts normalized. No organomegaly. Clinical improvement noted. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 02/01/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": \"NO\",\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Benign presentation\",\n      \"No previous oncology history\",\n      \"Resolved febrile illness\",\n      \"Blood counts normalized\",\n      \"No organomegaly\",\n      \"Clinical improvement noted\",\n      \"No malignancy identified\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": [\n      \"The initial reason for the PET-CT scan is not specified, but the report indicates a benign process or a resolved condition.\",\n      \"The febrile illness could have been infectious or inflammatory, now resolved.\"\n    ]\n  },\n  \"Final Diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 0,
      "timestamp": "2026-01-10T20:11:37.642841"
    },
    {
      "sample_idx": 1,
      "input": "26/10/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Brain Tumor - Medulloblastoma.\n\nFrom clinical notes: Brain Tumor - Medulloblastoma. Paediatric oncology assessment.\n\nFindings: posterior fossa mass with enhancement and hydrocephalus. Restricted diffusion. High-grade medulloblastoma on histology. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 26/10/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Clinical suspicion of Brain Tumor - Medulloblastoma.\",\n      \"Paediatric oncology assessment context.\",\n      \"PET-CT findings: posterior fossa mass with enhancement.\",\n      \"PET-CT findings: hydrocephalus.\",\n      \"PET-CT findings: Restricted diffusion.\",\n      \"Histology: High-grade medulloblastoma.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest medulloblastoma, other posterior fossa tumors in children (e.g., ependymoma, atypical teratoid/rhabdoid tumor (AT/RT)) could present similarly, although histology confirmed medulloblastoma.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"YES, malignancy is present. The report confirms a high-grade medulloblastoma, a malignant brain tumor, based on clinical suspicion, imaging findings (posterior fossa mass with enhancement, hydrocephalus, restricted diffusion), and definitive histology.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 1,
      "timestamp": "2026-01-10T20:11:37.642903"
    },
    {
      "sample_idx": 2,
      "input": "03/07/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 03/07/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"None\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"Reactive lymphadenopathy secondary to viral infection.\",\n      \"Node size decreasing on follow-up.\",\n      \"No atypical features.\",\n      \"No malignancy identified.\"\n    ],\n    \"Alternative Explanations\": [\n      \"Viral infection causing reactive lymphadenopathy.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"NO malignancy identified. Findings are consistent with reactive lymphadenopathy secondary to a viral infection, which is improving.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 2,
      "timestamp": "2026-01-10T20:11:37.642932"
    },
    {
      "sample_idx": 3,
      "input": "27/02/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Non-Hodgkin Lymphoma.\n\nFrom clinical notes: Non-Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: abdominal lymphadenopathy with mesenteric and retroperitoneal nodes. Burkitt lymphoma confirmed on biopsy. High LDH levels. Recommend MDT discussion and treatment planning.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 27/02/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Palpable mass.\",\n      \"Suspected Non-Hodgkin Lymphoma.\",\n      \"Burkitt lymphoma confirmed on biopsy.\",\n      \"High LDH levels.\",\n      \"Abdominal lymphadenopathy with mesenteric and retroperitoneal nodes.\"\n    ],\n    \"Findings Contradicting Malignancy\": [],\n    \"Alternative Explanations\": [\n      \"While Burkitt lymphoma is confirmed, the report mentions 'abdominal lymphadenopathy' which could potentially be caused by infections or inflammatory conditions, though the biopsy confirmation points strongly towards lymphoma.\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy?\": \"YES\",\n    \"Diagnosis\": \"Burkitt Lymphoma\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 3,
      "timestamp": "2026-01-10T20:11:37.642958"
    },
    {
      "sample_idx": 4,
      "input": "04/05/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Acute Lymphoblastic Leukemia.\n\nFrom clinical notes: Acute Lymphoblastic Leukemia. Paediatric oncology assessment.\n\nFindings: bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells. Immunophenotyping consistent with B-cell ALL. CNS involvement negative. Recommend MDT discussion and treatment planning.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 04/05/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Initial Assessment\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Reason for Request: Pancytopenia (often associated with bone marrow infiltration by leukemia).\",\n      \"Clinical notes explicitly state: Acute Lymphoblastic Leukemia.\",\n      \"Ultrasound findings: bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells (high percentage strongly indicative of leukemia).\",\n      \"Immunophenotyping consistent with B-cell ALL (confirms the specific type of leukemia).\"\n    ],\n    \"Contradicting Findings\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"Alternative Explanations\": [\n      \"While pancytopenia can have other causes, the bone marrow findings and clinical suspicion strongly point towards ALL.\",\n      \"Other causes of bone marrow infiltration (e.g., metastatic solid tumors, other hematologic malignancies) are less likely given the specific findings of lymphoblasts and B-cell ALL immunophenotype.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"YES, the report confirms the diagnosis of Acute Lymphoblastic Leukemia (ALL), specifically B-cell ALL, based on clinical suspicion, pancytopenia, and definitive bone marrow findings showing significant lymphoblast infiltration and characteristic immunophenotyping.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 4,
      "timestamp": "2026-01-10T20:11:37.642994"
    },
    {
      "sample_idx": 5,
      "input": "17/09/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 17/09/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"No malignancy identified.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Reactive lymphadenopathy secondary to viral infection.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"NO malignancy identified. The findings are consistent with reactive lymphadenopathy likely due to a viral infection, which is resolving as indicated by decreasing node size on follow-up.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 5,
      "timestamp": "2026-01-10T20:11:37.643014"
    },
    {
      "sample_idx": 6,
      "input": "11/07/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Lymphadenopathy. Suspected Neuroblastoma.\n\nFrom clinical notes: Neuroblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous suprarenal mass with calcifications. MIBG avidity present. Elevated urinary catecholamines. Stage III disease. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 11/07/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Large heterogeneous suprarenal mass\",\n      \"Calcifications within the mass\",\n      \"MIBG avidity (characteristic of neuroblastoma)\",\n      \"Elevated urinary catecholamines (characteristic of neuroblastoma)\",\n      \"Clinical suspicion of Neuroblastoma\",\n      \"Staging as Stage III disease (implies malignancy and spread)\",\n      \"Recommendation for MDT discussion and treatment planning (standard for malignancy)\"\n    ],\n    \"contradicting_findings\": [\n      \"None explicitly stated in the report\"\n    ],\n    \"alternative_explanations\": [\n      \"While other adrenal masses exist (e.g., adrenal hemorrhage, benign tumors), the combination of findings (heterogeneity, calcifications, MIBG avidity, elevated catecholamines) strongly points towards neuroblastoma, making alternatives less likely in this context.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_malignancy\": \"YES\",\n    \"diagnosis\": \"Neuroblastoma (Stage III)\",\n    \"rationale\": \"The report explicitly mentions suspected and likely Neuroblastoma, supported by characteristic imaging findings (suprarenal mass with calcifications, MIBG avidity) and biochemical evidence (elevated catecholamines). The staging as Stage III further confirms a malignant process. There are no findings presented that contradict this diagnosis.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 6,
      "timestamp": "2026-01-10T20:11:37.643051"
    },
    {
      "sample_idx": 7,
      "input": "21/03/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 21/03/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"Normal chest radiograph\",\n      \"Clear lung fields\",\n      \"No mediastinal mass\",\n      \"Heart size normal\",\n      \"No malignancy identified (explicit statement)\",\n      \"Reassurance provided\"\n    ],\n    \"alternative_explanations\": [\n      \"Benign condition causing symptoms (reason for request not specified)\",\n      \"Normal findings (if symptoms were vague or non-specific)\",\n      \"False negative (though unlikely given the explicit statement and normal findings)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 7,
      "timestamp": "2026-01-10T20:11:37.643085"
    },
    {
      "sample_idx": 8,
      "input": "08/02/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Normal CBC with age-appropriate values. No blast cells. Platelets adequate. Hemoglobin within normal limits. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 08/02/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal CBC with age-appropriate values.\",\n      \"No blast cells identified.\",\n      \"Platelets adequate.\",\n      \"Hemoglobin within normal limits.\",\n      \"Explicit statement: No malignancy identified.\",\n      \"Reassurance provided to the patient/family.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"The reason for request 'Rule out malignancy' suggests a clinical suspicion, but the findings do not support it.\",\n      \"The normal findings could indicate a benign condition or no significant pathology.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO\"\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 8,
      "timestamp": "2026-01-10T20:11:37.643108"
    },
    {
      "sample_idx": 9,
      "input": "25/04/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 25/04/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"malignancy_present\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Large heterogeneous left renal mass with pseudocapsule.\",\n      \"Suspected Wilms Tumor.\",\n      \"Wilms Tumor mentioned in clinical notes.\",\n      \"Favorable histology on biopsy.\",\n      \"Stage II classification.\",\n      \"Recommendation for MDT discussion and treatment planning (standard for malignancy).\"\n    ],\n    \"contradicting_findings\": [\n      \"None\"\n    ],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest Wilms Tumor, other pediatric renal masses (e.g., clear cell sarcoma of the kidney, rhabdoid tumor of the kidney) are possible, though less likely given the 'favorable histology' noted.\",\n      \"Pancytopenia could be related to the tumor, bone marrow involvement, or treatment effects, but is not directly contradictory to the tumor diagnosis.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"malignancy_present\": \"YES\",\n    \"diagnosis\": \"Wilms Tumor (Stage II, favorable histology)\",\n    \"justification\": \"The report explicitly mentions a suspected and clinically noted Wilms Tumor, supported by imaging findings of a large heterogeneous left renal mass, a biopsy confirming favorable histology, and staging as Stage II. The recommendation for MDT discussion further supports a malignant diagnosis requiring specialized care.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 9,
      "timestamp": "2026-01-10T20:11:37.643144"
    },
    {
      "sample_idx": 10,
      "input": "26/12/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Hodgkin Lymphoma.\n\nFrom clinical notes: Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: mediastinal lymphadenopathy with bulky anterior mediastinal mass. PET-CT showing FDG-avid nodes. Classical Hodgkin, nodular sclerosing type. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 26/12/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Pancytopenia (can be associated with lymphoma)\",\n      \"From clinical notes: Hodgkin Lymphoma (explicit clinical suspicion)\",\n      \"Findings: mediastinal lymphadenopathy with bulky anterior mediastinal mass (common presentation of Hodgkin Lymphoma)\",\n      \"PET-CT showing FDG-avid nodes (suggestive of malignancy, particularly lymphoma)\",\n      \"Classical Hodgkin, nodular sclerosing type (specific diagnosis of Hodgkin Lymphoma)\"\n    ],\n    \"contradicting_findings\": [\n      \"None explicitly stated in the provided report.\"\n    ],\n    \"alternative_explanations\": [\n      \"While the findings strongly point to Hodgkin Lymphoma, other causes of mediastinal masses and lymphadenopathy (e.g., infections like tuberculosis, other lymphomas, thymoma, germ cell tumors) should be considered, although less likely given the specific diagnosis provided.\",\n      \"Pancytopenia can have various causes, but in this context, it's likely related to the suspected lymphoma.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Classical Hodgkin Lymphoma, nodular sclerosing type\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 10,
      "timestamp": "2026-01-10T20:11:37.643179"
    },
    {
      "sample_idx": 11,
      "input": "18/09/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Neuroblastoma.\n\nFrom clinical notes: Neuroblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous suprarenal mass with calcifications. MIBG avidity present. Elevated urinary catecholamines. Stage III disease. Recommend MDT discussion and treatment planning.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 18/09/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Large heterogeneous suprarenal mass with calcifications\",\n      \"MIBG avidity present\",\n      \"Elevated urinary catecholamines\",\n      \"Clinical suspicion of Neuroblastoma\",\n      \"Staging indicates Stage III disease (suggestive of malignancy)\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While highly suggestive of neuroblastoma, other suprarenal masses (e.g., adrenal cortical carcinoma, pheochromocytoma - though less likely in this age group given context) could theoretically present similarly, but the combination of MIBG avidity and elevated catecholamines strongly points towards neuroblastoma.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Neuroblastoma (Stage III)\",\n    \"justification\": \"The presence of a large, heterogeneous suprarenal mass with calcifications, combined with MIBG avidity and elevated urinary catecholamines, in the context of clinical suspicion and paediatric oncology assessment, strongly supports the diagnosis of Neuroblastoma. The staging as Stage III further confirms a malignant process requiring oncological management.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 11,
      "timestamp": "2026-01-10T20:11:37.643212"
    },
    {
      "sample_idx": 12,
      "input": "15/12/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Hepatoblastoma.\n\nFrom clinical notes: Hepatoblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous hepatic mass with elevated AFP. Fetal histology subtype. PRETEXT stage II. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 15/12/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Pancytopenia (can be associated with malignancy)\",\n      \"Suspected Hepatoblastoma (a malignant liver tumor)\",\n      \"Clinical notes mention Hepatoblastoma\",\n      \"Findings: large heterogeneous hepatic mass (characteristic of tumor)\",\n      \"Findings: elevated AFP (Alpha-fetoprotein, a common tumor marker for Hepatoblastoma)\",\n      \"Findings: Fetal histology subtype (specific type of Hepatoblastoma)\",\n      \"Findings: PRETEXT stage II (staging system for Hepatoblastoma, indicating malignancy)\",\n      \"Recommendation: MDT discussion and treatment planning (standard for malignancy)\"\n    ],\n    \"contradicting_findings\": [\n      \"None\"\n    ],\n    \"alternative_explanations\": [\n      \"While pancytopenia can have other causes (e.g., infection, autoimmune disease, bone marrow failure), the context strongly points towards malignancy.\",\n      \"Other liver masses exist, but the combination of findings (AFP elevation, specific histology, staging) is highly suggestive of Hepatoblastoma.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_assessment\": \"YES\",\n    \"diagnosis_summary\": \"The report strongly indicates the presence of Hepatoblastoma, a malignant liver tumor, based on the clinical suspicion, imaging findings (large heterogeneous hepatic mass), elevated tumor marker (AFP), histological subtype (fetal), and staging (PRETEXT II).\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 12,
      "timestamp": "2026-01-10T20:11:37.643250"
    },
    {
      "sample_idx": 13,
      "input": "26/02/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Langerhans Cell Histiocytosis.\n\nFrom clinical notes: Langerhans Cell Histiocytosis. Paediatric oncology assessment.\n\nFindings: multiple lytic skull lesions with soft tissue component. CD1a and Langerin positive. Multisystem disease. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 26/02/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": \"NO\",\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Multiple lytic skull lesions with soft tissue component.\",\n      \"CD1a and Langerin positive.\",\n      \"Multisystem disease.\",\n      \"Clinical suspicion of Langerhans Cell Histiocytosis (LCH).\"\n    ],\n    \"Contradicting Findings\": [\n      \"The report explicitly states Langerhans Cell Histiocytosis (LCH), not malignancy.\"\n    ],\n    \"Alternative Explanations\": [\n      \"Langerhans Cell Histiocytosis (LCH) is a non-malignant disorder characterized by the proliferation of Langerhans cells. While it can behave aggressively and involve multiple systems, it is not typically classified as a primary malignancy in the same way as leukemia or lymphoma. The findings are consistent with LCH.\"\n    ]\n  },\n  \"Final Diagnosis\": \"NO\"\n}\n```\n",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 13,
      "timestamp": "2026-01-10T20:11:37.643277"
    },
    {
      "sample_idx": 14,
      "input": "08/09/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Post-viral lymphocytosis. Atypical lymphocytes resolving. Monospot positive. EBV serology confirms. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 08/09/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"Screening reason for request (suggests concern, but not confirmed malignancy)\",\n      \"Post-viral lymphocytosis with atypical lymphocytes resolving\",\n      \"Monospot positive\",\n      \"EBV serology confirms (Epstein-Barr Virus, associated with infectious mononucleosis)\",\n      \"Explicit statement: No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"alternative_explanations\": [\n      \"Infectious mononucleosis (given positive Monospot and EBV serology)\",\n      \"Reactive lymphocytosis secondary to viral infection\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\",\n    \"diagnosis\": \"No malignancy identified. Findings consistent with resolving infectious mononucleosis (EBV infection).\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 14,
      "timestamp": "2026-01-10T20:11:37.643302"
    },
    {
      "sample_idx": 15,
      "input": "14/07/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Bone pain. Suspected Acute Myeloid Leukemia.\n\nFrom clinical notes: Acute Myeloid Leukemia. Paediatric oncology assessment.\n\nFindings: myeloblasts accounting for 70% of marrow cellularity. Cytogenetic analysis reveals t(8;21) translocation. Favorable risk category. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 14/07/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"myeloblasts accounting for 70% of marrow cellularity (normal is typically <5%)\",\n      \"Cytogenetic analysis reveals t(8;21) translocation (a specific chromosomal abnormality strongly associated with Acute Myeloid Leukemia)\",\n      \"Clinical suspicion of Acute Myeloid Leukemia (AML)\",\n      \"Paediatric oncology assessment context (AML is a known paediatric malignancy)\"\n    ],\n    \"Contradicting Findings\": [\n      \"None\"\n    ],\n    \"Alternative Explanations\": [\n      \"While bone pain can have other causes, the high percentage of myeloblasts and specific translocation strongly point towards AML.\",\n      \"Other bone marrow disorders could theoretically cause increased blasts, but the specific t(8;21) translocation is highly characteristic of AML.\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Confirmed Diagnosis\": \"Acute Myeloid Leukemia (AML) with t(8;21) translocation\",\n    \"Rationale\": \"The bone marrow biopsy showing 70% myeloblasts, combined with the specific t(8;21) translocation, confirms the diagnosis of Acute Myeloid Leukemia. This finding aligns with the clinical suspicion and paediatric oncology context.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 15,
      "timestamp": "2026-01-10T20:11:37.643339"
    },
    {
      "sample_idx": 16,
      "input": "07/10/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Unexplained fever and weight loss. Suspected Rhabdomyosarcoma.\n\nFrom clinical notes: Rhabdomyosarcoma. Paediatric oncology assessment.\n\nFindings: parameningeal mass with intracranial extension. Embryonal rhabdomyosarcoma on biopsy. PAX-FOXO1 fusion negative. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 07/10/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Clinical suspicion of Rhabdomyosarcoma.\",\n      \"Biopsy confirms Embryonal rhabdomyosarcoma.\",\n      \"Presence of a parameningeal mass with intracranial extension, consistent with aggressive behaviour often seen in rhabdomyosarcoma.\"\n    ],\n    \"contradicting_findings\": [\n      \"PAX-FOXO1 fusion negative. While this fusion is common in alveolar rhabdomyosarcoma, its absence doesn't rule out embryonal rhabdomyosarcoma, which is the diagnosed subtype here. It's more a characteristic of a different subtype, not a contradiction to the overall diagnosis of malignancy.\"\n    ],\n    \"alternative_explanations\": [\n      \"While the biopsy confirms rhabdomyosarcoma, the initial symptoms (fever, weight loss) are non-specific and could be associated with various conditions (infection, autoimmune disease, other malignancies). However, the biopsy result provides a definitive diagnosis in this context.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Embryonal Rhabdomyosarcoma (parameningeal location with intracranial extension)\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 16,
      "timestamp": "2026-01-10T20:11:37.643372"
    },
    {
      "sample_idx": 17,
      "input": "06/04/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 06/04/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal chest radiograph\",\n      \"Clear lung fields\",\n      \"No mediastinal mass\",\n      \"Heart size normal\",\n      \"No malignancy identified (explicit statement)\",\n      \"Reassurance provided\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Screening procedure\",\n      \"No underlying pathology found\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_assessment\": \"NO\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and describes normal findings on chest radiograph, including clear lung fields and no mediastinal mass. The reason for the request was screening, and reassurance was provided, further supporting the absence of malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 17,
      "timestamp": "2026-01-10T20:11:37.643397"
    },
    {
      "sample_idx": 18,
      "input": "23/05/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Bone pain. Suspected Brain Tumor - Medulloblastoma.\n\nFrom clinical notes: Brain Tumor - Medulloblastoma. Paediatric oncology assessment.\n\nFindings: posterior fossa mass with enhancement and hydrocephalus. Restricted diffusion. High-grade medulloblastoma on histology. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 23/05/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Posterior fossa mass with enhancement\",\n      \"Hydrocephalus\",\n      \"Restricted diffusion (suggestive of high cellularity/cytotoxicity)\",\n      \"High-grade medulloblastoma on histology\",\n      \"Clinical suspicion of Medulloblastoma\",\n      \"Paediatric oncology assessment context\"\n    ],\n    \"contradicting_findings\": [\n      \"None\"\n    ],\n    \"alternative_explanations\": [\n      \"While other posterior fossa tumors exist (e.g., ependymoma, astrocytoma), the histology specifically identifies medulloblastoma.\",\n      \"Hydrocephalus can have non-malignant causes, but in the context of a posterior fossa mass, malignancy is highly likely.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis_details\": \"High-grade medulloblastoma located in the posterior fossa, causing hydrocephalus.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 18,
      "timestamp": "2026-01-10T20:11:37.643426"
    },
    {
      "sample_idx": 19,
      "input": "09/07/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Neuroblastoma.\n\nFrom clinical notes: Neuroblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous suprarenal mass with calcifications. MIBG avidity present. Elevated urinary catecholamines. Stage III disease. Recommend MDT discussion and treatment planning.\n\nDr James Chen, Consultant Paediatric Oncologist 09/07/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Large heterogeneous suprarenal mass\",\n      \"Calcifications within the mass\",\n      \"MIBG avidity\",\n      \"Elevated urinary catecholamines\",\n      \"Clinical suspicion of Neuroblastoma\",\n      \"Stage III disease designation\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While highly suggestive of Neuroblastoma, other suprarenal masses (e.g., adrenal cortical carcinoma, pheochromocytoma, ganglioneuroma) could theoretically present with some similar features, although the combination of findings strongly points towards Neuroblastoma.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"YES, malignancy is present. The findings are highly consistent with Neuroblastoma, a malignant tumor of the sympathetic nervous system commonly found in children, originating in the adrenal gland (suprarenal mass).\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 19,
      "timestamp": "2026-01-10T20:11:37.643456"
    },
    {
      "sample_idx": 20,
      "input": "18/08/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 18/08/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Reason for Request: Pancytopenia (can be associated with malignancy).\",\n      \"Clinical notes: Wilms Tumor (explicitly stated).\",\n      \"Findings: Large heterogeneous left renal mass (highly suspicious for tumor).\",\n      \"Findings: Favorable histology on biopsy (confirms malignancy, specifically Wilms Tumor).\",\n      \"Stage II (indicates malignancy has spread beyond the kidney but is still potentially curable).\"\n    ],\n    \"Contradicting Findings\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"Alternative Explanations\": [\n      \"While pancytopenia can have other causes (e.g., infection, autoimmune disease, bone marrow failure), the presence of a large renal mass and a biopsy confirming favorable histology strongly points towards Wilms Tumor as the primary cause in this context.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed Diagnosis\": \"YES, malignancy is present. The report confirms a diagnosis of Wilms Tumor, Stage II, based on clinical suspicion, imaging findings (large heterogeneous left renal mass), and biopsy results (favorable histology).\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 20,
      "timestamp": "2026-01-10T20:11:37.643490"
    },
    {
      "sample_idx": 21,
      "input": "13/03/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 13/03/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy\": \"NO\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"No previous oncology history\",\n      \"Normal brain MRI for age\",\n      \"No mass lesion identified\",\n      \"No abnormal enhancement\",\n      \"Explicit statement: No malignancy identified\",\n      \"Reassurance provided to patient\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": [\n      \"Headaches attributed to migraine (non-malignant cause)\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 21,
      "timestamp": "2026-01-10T20:11:37.643513"
    },
    {
      "sample_idx": 22,
      "input": "18/10/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 18/10/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Palpable mass\",\n      \"Suspected Wilms Tumor\",\n      \"Clinical notes mention Wilms Tumor\",\n      \"Large heterogeneous left renal mass\",\n      \"Favorable histology on biopsy\",\n      \"Stage II\"\n    ],\n    \"contradicting_findings\": [\n      \"No vascular invasion\"\n    ],\n    \"alternative_explanations\": [\n      \"Other pediatric renal tumors (e.g., clear cell sarcoma of the kidney, rhabdoid tumor of the kidney), although Wilms Tumor is strongly suspected and biopsy confirmed favorable histology.\",\n      \"Benign renal mass (less likely given the description and suspicion)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Wilms Tumor (Stage II, favorable histology)\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 22,
      "timestamp": "2026-01-10T20:11:37.643542"
    },
    {
      "sample_idx": 23,
      "input": "02/05/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 02/05/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy\": \"NO\"\n  },\n  \"Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"Normal brain MRI for age\",\n      \"No mass lesion\",\n      \"No abnormal enhancement\",\n      \"Headaches attributed to migraine\",\n      \"No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"Alternative Explanations\": [\n      \"Migraine headaches\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 23,
      "timestamp": "2026-01-10T20:11:37.643563"
    },
    {
      "sample_idx": 24,
      "input": "16/05/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 16/05/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"Normal brain MRI for age.\",\n      \"No mass lesion.\",\n      \"No abnormal enhancement.\",\n      \"No malignancy identified.\",\n      \"Reassurance provided.\"\n    ],\n    \"alternative_explanations\": [\n      \"Headaches attributed to migraine (a non-malignant condition).\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 24,
      "timestamp": "2026-01-10T20:11:37.643585"
    },
    {
      "sample_idx": 25,
      "input": "16/05/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Unexplained fever and weight loss. Suspected Ewing Sarcoma.\n\nFrom clinical notes: Ewing Sarcoma. Paediatric oncology assessment.\n\nFindings: permeative bone destruction in left femoral diaphysis with large soft tissue mass. Onion-skin periosteal reaction. EWSR1 fusion positive. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 16/05/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Unexplained fever and weight loss (constitutional symptoms often associated with malignancy)\",\n      \"Suspected Ewing Sarcoma (a known malignancy)\",\n      \"Permeative bone destruction (characteristic of aggressive bone lesions, including malignancy)\",\n      \"Large soft tissue mass (often associated with malignant bone tumours)\",\n      \"Onion-skin periosteal reaction (classic radiographic sign often seen in Ewing Sarcoma)\",\n      \"EWSR1 fusion positive (specific genetic marker strongly associated with Ewing Sarcoma)\"\n    ],\n    \"Findings Contradicting Malignancy\": [],\n    \"Alternative Explanations\": [\n      \"Infection (osteomyelitis) can cause bone destruction and periosteal reaction, but EWSR1 fusion positivity makes this highly unlikely.\",\n      \"Benign bone tumours (e.g., osteoid osteoma, giant cell tumour) are less likely given the permeative destruction, large soft tissue mass, onion-skin reaction, and EWSR1 fusion.\",\n      \"Metastatic disease (less common in this age group without a known primary, but possible).\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Conclusion\": \"YES, malignancy is present. The findings are highly consistent with Ewing Sarcoma.\",\n    \"Justification\": \"The combination of clinical suspicion (Ewing Sarcoma), characteristic radiographic findings (permeative destruction, soft tissue mass, onion-skin periosteal reaction), and the specific genetic marker (EWSR1 fusion positivity) strongly confirms the presence of Ewing Sarcoma, a malignant bone tumour.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 25,
      "timestamp": "2026-01-10T20:11:37.643625"
    },
    {
      "sample_idx": 26,
      "input": "13/08/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Non-Hodgkin Lymphoma.\n\nFrom clinical notes: Non-Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: abdominal lymphadenopathy with mesenteric and retroperitoneal nodes. Burkitt lymphoma confirmed on biopsy. High LDH levels. Recommend MDT discussion and treatment planning.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 13/08/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Suspected Non-Hodgkin Lymphoma\",\n      \"Burkitt lymphoma confirmed on biopsy\",\n      \"Abdominal lymphadenopathy (mesenteric and retroperitoneal nodes)\",\n      \"High LDH levels (often associated with high cell turnover in lymphomas)\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"None explicitly stated in the report\"\n    ],\n    \"Alternative Explanations\": [\n      \"While the report confirms Burkitt lymphoma, the initial presentation was pancytopenia and suspected Non-Hodgkin Lymphoma. Pancytopenia can have other causes (e.g., aplastic anemia, infections, autoimmune disorders), but the biopsy confirmation points strongly towards lymphoma as the underlying cause in this case.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed Diagnosis\": \"Burkitt lymphoma\",\n    \"Assessment Revision\": \"Initial suspicion of Non-Hodgkin Lymphoma was confirmed as Burkitt lymphoma via biopsy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 26,
      "timestamp": "2026-01-10T20:11:37.643656"
    },
    {
      "sample_idx": 27,
      "input": "25/06/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Healing fracture - normal process. No pathological features. Bone density normal. Trauma history consistent. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 25/06/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings SUPPORTING malignancy\": [],\n    \"Findings CONTRADICTING malignancy\": [\n      \"No malignancy identified.\",\n      \"Healing fracture - normal process.\",\n      \"No pathological features.\",\n      \"Bone density normal.\",\n      \"Trauma history consistent.\"\n    ],\n    \"Alternative Explanations\": [\n      \"Healing fracture from trauma (non-malignant).\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Conclusion\": \"NO malignancy identified. The findings are consistent with a healing fracture from trauma, a normal process without pathological features.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 27,
      "timestamp": "2026-01-10T20:11:37.643678"
    },
    {
      "sample_idx": 28,
      "input": "01/07/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Benign bone cyst - resolved. No aggressive features. Normal bone density. No recurrence on imaging. No malignancy identified. Reassurance provided.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 01/07/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Benign bone cyst - resolved\",\n      \"No aggressive features\",\n      \"Normal bone density\",\n      \"No recurrence on imaging\",\n      \"No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Resolved benign bone cyst (as stated)\",\n      \"Normal bone findings\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and describes findings consistent with a resolved benign condition ('Benign bone cyst - resolved') with no aggressive features or recurrence. The reassurance provided further supports the absence of malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 28,
      "timestamp": "2026-01-10T20:11:37.643703"
    },
    {
      "sample_idx": 29,
      "input": "04/12/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Neuroblastoma.\n\nFrom clinical notes: Neuroblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous suprarenal mass with calcifications. MIBG avidity present. Elevated urinary catecholamines. Stage III disease. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 04/12/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Palpable mass\",\n      \"Suspected Neuroblastoma\",\n      \"Clinical notes mention Neuroblastoma\",\n      \"Large heterogeneous suprarenal mass with calcifications on PET-CT\",\n      \"MIBG avidity present on PET-CT\",\n      \"Elevated urinary catecholamines\",\n      \"Stage III disease designation\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Other adrenal masses (e.g., adrenal cortical carcinoma, ganglioneuroma, pheochromocytoma), though less likely given the combination of MIBG avidity, elevated catecholamines, and clinical suspicion.\",\n      \"Inflammatory or infectious process causing a mass (less likely given heterogeneity, calcifications, and MIBG avidity).\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Neuroblastoma, Stage III\",\n    \"reasoning\": \"The report strongly indicates malignancy, specifically Neuroblastoma. The presence of a large, heterogeneous suprarenal mass with calcifications, MIBG avidity (characteristic of neuroblastic tumors), elevated urinary catecholamines, and the clinical suspicion/designation of Neuroblastoma and Stage III disease collectively point towards a malignant diagnosis.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 29,
      "timestamp": "2026-01-10T20:11:37.643743"
    },
    {
      "sample_idx": 30,
      "input": "15/07/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Lymphadenopathy. Suspected Brain Tumor - Medulloblastoma.\n\nFrom clinical notes: Brain Tumor - Medulloblastoma. Paediatric oncology assessment.\n\nFindings: posterior fossa mass with enhancement and hydrocephalus. Restricted diffusion. High-grade medulloblastoma on histology. Recommend MDT discussion and treatment planning.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 15/07/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Posterior fossa mass with enhancement\",\n      \"Hydrocephalus (often associated with brain tumors)\",\n      \"Restricted diffusion (suggestive of high cellularity, common in high-grade tumors)\",\n      \"High-grade medulloblastoma on histology (definitive confirmation of malignancy)\",\n      \"Clinical suspicion of Medulloblastoma\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While hydrocephalus can have other causes, the presence of a posterior fossa mass makes a tumor the most likely cause.\",\n      \"Other posterior fossa tumors could be considered, but histology confirms medulloblastoma.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"High-grade Medulloblastoma\"\n  }\n}\n```\n\"\"\"\n```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Clinical suspicion of Brain Tumor - Medulloblastoma\",\n      \"Posterior fossa mass with enhancement\",\n      \"Hydrocephalus\",\n      \"Restricted diffusion\",\n      \"High-grade medulloblastoma on histology\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Hydrocephalus can have non-tumor causes, but is likely secondary to the mass.\",\n      \"Other posterior fossa masses exist, but histology confirms medulloblastoma.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"High-grade Medulloblastoma\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 30,
      "timestamp": "2026-01-10T20:11:37.643770"
    },
    {
      "sample_idx": 31,
      "input": "02/04/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 02/04/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal chest radiograph.\",\n      \"Clear lung fields.\",\n      \"No mediastinal mass.\",\n      \"Heart size normal.\",\n      \"Explicit statement: 'No malignancy identified.'\",\n      \"Reason for Request: Benign presentation.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign presentation as stated in the history.\",\n      \"Normal physiological findings.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\",\n    \"summary\": \"Based on the normal chest X-ray findings and the explicit statement by the consulting paediatric oncologist, there is no evidence of malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 31,
      "timestamp": "2026-01-10T20:11:37.643792"
    },
    {
      "sample_idx": 32,
      "input": "04/10/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Germ Cell Tumor.\n\nFrom clinical notes: Germ Cell Tumor. Paediatric oncology assessment.\n\nFindings: sacrococcygeal mass with mixed solid and cystic components. Elevated AFP and beta-hCG. Yolk sac tumor elements present. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 04/10/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Palpable mass\",\n      \"Suspected Germ Cell Tumor\",\n      \"Clinical notes mention Germ Cell Tumor\",\n      \"Sacrococcygeal mass with mixed solid and cystic components\",\n      \"Elevated AFP (Alpha-fetoprotein)\",\n      \"Elevated beta-hCG (beta-human chorionic gonadotropin)\",\n      \"Yolk sac tumor elements present\",\n      \"Recommendation for MDT (Multidisciplinary Team) discussion and treatment planning\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest malignancy, other rare sacrococcygeal masses (e.g., teratomas, other benign cystic lesions) could be considered, although less likely given the specific tumor markers and histology mentioned.\",\n      \"Inflammatory or infectious processes could cause masses, but the specific tumor markers (AFP, beta-hCG) and histology (yolk sac elements) make these highly improbable.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_diagnosis\": \"YES\",\n    \"diagnosis_details\": \"The report strongly indicates a malignant Germ Cell Tumor, specifically with Yolk Sac Tumor elements, based on the presence of a sacrococcygeal mass, elevated tumor markers (AFP, beta-hCG), and histological findings. The recommendation for MDT discussion further supports the need for treatment planning for a likely malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 32,
      "timestamp": "2026-01-10T20:11:37.643828"
    },
    {
      "sample_idx": 33,
      "input": "24/11/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Hodgkin Lymphoma.\n\nFrom clinical notes: Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: mediastinal lymphadenopathy with bulky anterior mediastinal mass. PET-CT showing FDG-avid nodes. Classical Hodgkin, nodular sclerosing type. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 24/11/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Palpable mass\",\n      \"Suspected Hodgkin Lymphoma\",\n      \"Clinical notes mention Hodgkin Lymphoma\",\n      \"Mediastinal lymphadenopathy\",\n      \"Bulky anterior mediastinal mass\",\n      \"PET-CT showing FDG-avid nodes\",\n      \"Classical Hodgkin, nodular sclerosing type (histological confirmation implied)\",\n      \"Recommendation for MDT discussion and treatment planning (standard for malignancy)\"\n    ],\n    \"contradicting_findings\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"alternative_explanations\": [\n      \"While the report strongly suggests Hodgkin Lymphoma, other causes of mediastinal mass and lymphadenopathy exist (e.g., infection, other lymphomas, germ cell tumors, thymoma). However, the specific mention of 'Classical Hodgkin, nodular sclerosing type' strongly points towards this diagnosis.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Classical Hodgkin Lymphoma, nodular sclerosing type\",\n    \"confidence\": \"High\",\n    \"justification\": \"The report explicitly states 'Hodgkin Lymphoma' in the clinical notes and confirms 'Classical Hodgkin, nodular sclerosing type'. Imaging findings (mediastinal lymphadenopathy, bulky mass, FDG-avid nodes) are consistent with lymphoma. The recommendation for MDT discussion further supports a malignant diagnosis requiring specialized care.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 33,
      "timestamp": "2026-01-10T20:11:37.643878"
    },
    {
      "sample_idx": 34,
      "input": "07/03/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Normal CBC with age-appropriate values. No blast cells. Platelets adequate. Hemoglobin within normal limits. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 07/03/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"Normal CBC with age-appropriate values.\",\n      \"No blast cells identified.\",\n      \"Platelets adequate.\",\n      \"Hemoglobin within normal limits.\",\n      \"Explicit statement: 'No malignancy identified.'\"\n    ],\n    \"Alternative Explanations\": [\n      \"Routine surveillance finding.\",\n      \"Normal bone marrow findings.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed/Revised Diagnosis\": \"NO malignancy identified. The report indicates normal bone marrow findings consistent with routine surveillance.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 34,
      "timestamp": "2026-01-10T20:11:37.643901"
    },
    {
      "sample_idx": 35,
      "input": "04/10/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Benign soft tissue mass - lipoma confirmed. Well-circumscribed. No enhancement. No intervention required. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 04/10/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Report explicitly states 'No malignancy identified'.\",\n      \"Findings describe a 'Benign soft tissue mass - lipoma confirmed'.\",\n      \"The mass is described as 'Well-circumscribed' and shows 'No enhancement', features typically associated with benign lesions.\",\n      \"The report concludes with 'Reassurance provided' and 'No intervention required'.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"The finding is a benign lipoma, a common type of fatty tumor.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\",\n    \"conclusion\": \"The report definitively concludes that no malignancy was identified, and the finding is a benign lipoma.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 35,
      "timestamp": "2026-01-10T20:11:37.643926"
    },
    {
      "sample_idx": 36,
      "input": "04/01/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 04/01/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy_present\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal chest radiograph.\",\n      \"Clear lung fields.\",\n      \"No mediastinal mass.\",\n      \"Heart size normal.\",\n      \"No malignancy identified (explicitly stated).\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Screening procedure, potentially for underlying condition or risk factor, but no malignancy found.\",\n      \"False negative (although unlikely given the explicit statement and normal findings).\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"final_assessment\": \"NO\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and describes normal findings on the chest radiograph, including clear lung fields and no mediastinal mass. The biopsy was performed as a screening measure, and the results are reassuring.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 36,
      "timestamp": "2026-01-10T20:11:37.643955"
    },
    {
      "sample_idx": 37,
      "input": "02/04/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Osteosarcoma.\n\nFrom clinical notes: Osteosarcoma. Paediatric oncology assessment.\n\nFindings: destructive lesion in distal femur with soft tissue component. Sunburst periosteal reaction. Elevated alkaline phosphatase. Recommend MDT discussion and treatment planning.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 02/04/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Destructive lesion in distal femur with soft tissue component\",\n      \"Sunburst periosteal reaction\",\n      \"Elevated alkaline phosphatase (often associated with bone turnover, common in osteosarcoma)\",\n      \"Clinical suspicion of Osteosarcoma from clinical notes\",\n      \"Paediatric oncology assessment requested\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Ewing sarcoma (can also present with bone lesions and periosteal reaction)\",\n      \"Infection (osteomyelitis) (can cause destructive lesions, though sunburst reaction is less typical)\",\n      \"Metastatic disease (less likely in a paediatric patient without known primary)\",\n      \"Benign bone tumor (e.g., giant cell tumor, chondroblastoma) (less likely given the aggressive features described)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"assessment\": \"The findings strongly support the clinical suspicion of Osteosarcoma. The combination of a destructive bone lesion with a soft tissue component and a characteristic sunburst periosteal reaction in a paediatric patient is highly suggestive of malignancy, specifically osteosarcoma. Elevated alkaline phosphatase further supports this. While other diagnoses are possible, osteosarcoma is the most likely diagnosis based on the provided information.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 37,
      "timestamp": "2026-01-10T20:11:37.643992"
    },
    {
      "sample_idx": 38,
      "input": "05/03/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Lymphadenopathy. Suspected Osteosarcoma.\n\nFrom clinical notes: Osteosarcoma. Paediatric oncology assessment.\n\nFindings: destructive lesion in distal femur with soft tissue component. Sunburst periosteal reaction. Elevated alkaline phosphatase. Recommend MDT discussion and treatment planning.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 05/03/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Destructive lesion in distal femur with soft tissue component\",\n      \"Sunburst periosteal reaction\",\n      \"Clinical suspicion of Osteosarcoma\",\n      \"Elevated alkaline phosphatase (often associated with bone turnover/malignancy)\",\n      \"Paediatric oncology assessment context\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Infection (osteomyelitis) can sometimes present with destructive lesions and periosteal reaction, but the 'sunburst' pattern is highly suggestive of osteosarcoma.\",\n      \"Benign bone tumors (e.g., giant cell tumor, chondroblastoma) are less likely given the aggressive features described (destructive, soft tissue component, sunburst pattern).\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"assessment\": \"YES\",\n    \"reasoning\": \"The combination of a destructive bone lesion in the distal femur, a characteristic sunburst periosteal reaction, soft tissue involvement, elevated alkaline phosphatase, and the clinical suspicion strongly points towards a malignant bone tumor, highly likely Osteosarcoma, especially in the context of a paediatric oncology assessment.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 38,
      "timestamp": "2026-01-10T20:11:37.644028"
    },
    {
      "sample_idx": 39,
      "input": "01/11/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Post-viral lymphocytosis. Atypical lymphocytes resolving. Monospot positive. EBV serology confirms. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 01/11/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"No malignancy identified.\"\n    ],\n    \"alternative_explanations\": [\n      \"Post-viral lymphocytosis\",\n      \"Atypical lymphocytes resolving\",\n      \"Monospot positive\",\n      \"EBV serology confirms\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and provides alternative explanations consistent with a recent Epstein-Barr Virus (EBV) infection (infectious mononucleosis), including post-viral lymphocytosis, resolving atypical lymphocytes, a positive Monospot test, and confirmed EBV serology. The request was for screening in a patient with no previous oncology history, further reducing the likelihood of malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 39,
      "timestamp": "2026-01-10T20:11:37.644053"
    },
    {
      "sample_idx": 40,
      "input": "26/04/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 26/04/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Reason for Request: Pancytopenia (can be associated with bone marrow involvement by malignancy, although not directly indicative of the primary tumor).\",\n      \"From clinical notes: Wilms Tumor (explicitly states suspected/diagnosed Wilms Tumor, which is a malignancy).\",\n      \"Findings: large heterogeneous left renal mass with pseudocapsule (describes a suspicious mass, highly characteristic of Wilms Tumor).\",\n      \"Findings: Favorable histology on biopsy (confirms the mass is a Wilms Tumor, a malignancy, and indicates a better prognosis subtype).\",\n      \"Findings: Stage II (confirms the tumor is staged, implying a confirmed diagnosis of malignancy).\",\n      \"Recommend MDT discussion and treatment planning (standard procedure for confirmed malignancy).\"\n    ],\n    \"Contradicting Findings\": [\n      \"No vascular invasion (this is a favorable prognostic factor but does not contradict malignancy).\",\n      \"Pancytopenia (While potentially related to malignancy, it's non-specific and could have other causes. However, in the context of a suspected Wilms tumor, it raises concern for bone marrow involvement).\"\n    ],\n    \"Alternative Explanations\": [\n      \"Pancytopenia could be due to other causes (e.g., aplastic anemia, infection, autoimmune disease), but the clinical context strongly points towards Wilms Tumor.\",\n      \"The renal mass could theoretically be a benign tumor or inflammatory process, but the biopsy result ('Favorable histology on biopsy') confirms it as Wilms Tumor.\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy\": \"YES\",\n    \"Diagnosis\": \"Wilms Tumor (Stage II, Favorable Histology)\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 40,
      "timestamp": "2026-01-10T20:11:37.644094"
    },
    {
      "sample_idx": 41,
      "input": "18/11/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Lymphadenopathy. Suspected Hodgkin Lymphoma.\n\nFrom clinical notes: Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: mediastinal lymphadenopathy with bulky anterior mediastinal mass. PET-CT showing FDG-avid nodes. Classical Hodgkin, nodular sclerosing type. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 18/11/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Lymphadenopathy.\",\n      \"From clinical notes: Hodgkin Lymphoma.\",\n      \"Findings: mediastinal lymphadenopathy with bulky anterior mediastinal mass.\",\n      \"PET-CT showing FDG-avid nodes.\",\n      \"Classical Hodgkin, nodular sclerosing type.\",\n      \"Recommend MDT discussion and treatment planning.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": []\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_diagnosis\": \"YES, Hodgkin Lymphoma (Classical, nodular sclerosing type)\",\n    \"rationale\": \"The report explicitly states 'Hodgkin Lymphoma' in the clinical notes and confirms 'Classical Hodgkin, nodular sclerosing type' in the findings section. The presence of mediastinal lymphadenopathy, a bulky anterior mediastinal mass, and FDG-avid nodes on PET-CT are characteristic findings supporting this diagnosis. The recommendation for MDT discussion and treatment planning further reinforces the presence of a malignancy requiring intervention.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 41,
      "timestamp": "2026-01-10T20:11:37.644127"
    },
    {
      "sample_idx": 42,
      "input": "20/04/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Post-viral lymphocytosis. Atypical lymphocytes resolving. Monospot positive. EBV serology confirms. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 20/04/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"No malignancy identified.\"\n    ],\n    \"alternative_explanations\": [\n      \"Post-viral lymphocytosis\",\n      \"Atypical lymphocytes resolving\",\n      \"Monospot positive\",\n      \"EBV serology confirms (Infectious Mononucleosis)\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 42,
      "timestamp": "2026-01-10T20:11:37.644144"
    },
    {
      "sample_idx": 43,
      "input": "20/01/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 20/01/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Initial Assessment\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"Normal brain MRI for age\",\n      \"No mass lesion identified\",\n      \"No abnormal enhancement observed\",\n      \"Explicit statement: No malignancy identified\",\n      \"Reassurance provided to the patient\"\n    ],\n    \"Alternative Explanations\": [\n      \"Headaches attributed to migraine (a benign condition)\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 43,
      "timestamp": "2026-01-10T20:11:37.644163"
    },
    {
      "sample_idx": 44,
      "input": "22/11/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Ewing Sarcoma.\n\nFrom clinical notes: Ewing Sarcoma. Paediatric oncology assessment.\n\nFindings: permeative bone destruction in left femoral diaphysis with large soft tissue mass. Onion-skin periosteal reaction. EWSR1 fusion positive. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 22/11/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Permeative bone destruction in left femoral diaphysis\",\n      \"Large soft tissue mass\",\n      \"Onion-skin periosteal reaction\",\n      \"EWSR1 fusion positive\",\n      \"Clinical suspicion of Ewing Sarcoma\",\n      \"Paediatric oncology assessment context\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest Ewing Sarcoma, other bone malignancies (e.g., osteosarcoma, lymphoma) or even aggressive infections (osteomyelitis) could potentially present with some similar features, although the combination, especially the EWSR1 fusion, makes Ewing Sarcoma highly likely.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_or_revised_assessment\": \"YES\",\n    \"diagnosis\": \"Ewing Sarcoma\",\n    \"justification\": \"The combination of permeative bone destruction, a large soft tissue mass, onion-skin periosteal reaction, and a positive EWSR1 fusion gene test in a paediatric patient with clinical suspicion strongly confirms the diagnosis of Ewing Sarcoma.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 44,
      "timestamp": "2026-01-10T20:11:37.644200"
    },
    {
      "sample_idx": 45,
      "input": "06/05/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 06/05/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"Normal brain MRI for age.\",\n      \"No mass lesion.\",\n      \"No abnormal enhancement.\",\n      \"No malignancy identified.\"\n    ],\n    \"alternative_explanations\": [\n      \"Headaches attributed to migraine.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 45,
      "timestamp": "2026-01-10T20:11:37.644217"
    },
    {
      "sample_idx": 46,
      "input": "24/10/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Physiological splenomegaly for age. No focal lesions. Normal echo texture. Benign finding. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 24/10/2025, 00:00",
      "response": "```json\n{\n  \"step1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"No focal lesions identified on X-ray.\",\n      \"Normal echo texture observed.\",\n      \"Report explicitly states 'Benign finding'.\",\n      \"Report explicitly states 'No malignancy identified'.\",\n      \"Reassurance provided to the patient.\"\n    ],\n    \"contradicting_findings\": [\n      \"Physiological splenomegaly for age.\"\n    ],\n    \"alternative_explanations\": [\n      \"Physiological splenomegaly is a common finding in children and adolescents and is not indicative of malignancy in this context.\",\n      \"The splenomegaly is described as 'physiological', meaning it's considered a normal variation for the patient's age.\"\n    ]\n  },\n  \"step3_final_diagnosis\": {\n    \"conclusion\": \"The initial assessment of NO malignancy is confirmed. The findings strongly support a benign condition, with the splenomegaly being attributed to physiological causes rather than malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 46,
      "timestamp": "2026-01-10T20:11:37.644247"
    },
    {
      "sample_idx": 47,
      "input": "01/02/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 01/02/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"No malignancy identified.\",\n      \"Reactive lymphadenopathy secondary to viral infection.\",\n      \"Node size decreasing on follow-up.\",\n      \"No atypical features.\"\n    ],\n    \"alternative_explanations\": [\n      \"Viral infection causing reactive lymphadenopathy.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 47,
      "timestamp": "2026-01-10T20:11:37.644264"
    },
    {
      "sample_idx": 48,
      "input": "03/10/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Lymphadenopathy. Suspected Osteosarcoma.\n\nFrom clinical notes: Osteosarcoma. Paediatric oncology assessment.\n\nFindings: destructive lesion in distal femur with soft tissue component. Sunburst periosteal reaction. Elevated alkaline phosphatase. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 03/10/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Initial Assessment\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Destructive lesion in distal femur with soft tissue component\",\n      \"Sunburst periosteal reaction\",\n      \"Elevated alkaline phosphatase\",\n      \"Clinical suspicion of Osteosarcoma\",\n      \"Paediatric oncology assessment context\"\n    ],\n    \"Contradicting Findings\": [\n      \"None explicitly stated in the report\"\n    ],\n    \"Alternative Explanations\": [\n      \"While Osteosarcoma is strongly suspected, other bone malignancies (e.g., Ewing sarcoma) or aggressive benign bone lesions could theoretically present with some similar features, although the 'sunburst' pattern is highly characteristic of Osteosarcoma.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"YES, highly suspicious for Osteosarcoma based on imaging findings and clinical context.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 48,
      "timestamp": "2026-01-10T20:11:37.644291"
    },
    {
      "sample_idx": 49,
      "input": "05/08/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 05/08/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reactive lymphadenopathy secondary to viral infection.\",\n      \"Node size decreasing on follow-up.\",\n      \"No atypical features.\",\n      \"No malignancy identified.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Viral infection causing reactive lymphadenopathy.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO malignancy identified. The findings are consistent with reactive lymphadenopathy secondary to a viral infection, which is resolving as indicated by decreasing node size.\"\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 49,
      "timestamp": "2026-01-10T20:11:37.644310"
    },
    {
      "sample_idx": 50,
      "input": "02/05/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 02/05/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Initial Assessment\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"Benign presentation\",\n      \"No previous oncology history\",\n      \"Normal chest radiograph\",\n      \"Clear lung fields\",\n      \"No mediastinal mass\",\n      \"Heart size normal\",\n      \"No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"Alternative Explanations\": [\n      \"Benign condition\",\n      \"Normal findings\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 50,
      "timestamp": "2026-01-10T20:11:37.644332"
    },
    {
      "sample_idx": 51,
      "input": "26/07/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Benign soft tissue mass - lipoma confirmed. Well-circumscribed. No enhancement. No intervention required. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 26/07/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Benign soft tissue mass - lipoma confirmed.\",\n      \"Well-circumscribed.\",\n      \"No enhancement.\",\n      \"No malignancy identified.\",\n      \"Reassurance provided.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign soft tissue mass (lipoma) as stated in the report.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"NO malignancy identified. The findings are consistent with a benign lipoma.\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and confirms the mass as a 'Benign soft tissue mass - lipoma'. Features like being 'Well-circumscribed' and having 'No enhancement' further support a benign nature.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 51,
      "timestamp": "2026-01-10T20:11:37.644358"
    },
    {
      "sample_idx": 52,
      "input": "25/03/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Bone pain. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 25/03/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Suspected Wilms Tumor\",\n      \"Wilms Tumor mentioned in clinical notes\",\n      \"Large heterogeneous left renal mass\",\n      \"Favorable histology on biopsy\",\n      \"Stage II diagnosis\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign renal tumor (less likely given biopsy and staging)\",\n      \"Inflammatory process (unlikely given mass characteristics and biopsy)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Wilms Tumor (Stage II)\"\n  }\n}\n```\n\"\"\"\n```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Bone pain. Suspected Wilms Tumor.\",\n      \"From clinical notes: Wilms Tumor. Paediatric oncology assessment.\",\n      \"Findings: large heterogeneous left renal mass with pseudocapsule.\",\n      \"Favorable histology on biopsy.\",\n      \"Stage II diagnosis.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign renal tumor (less likely given biopsy and staging)\",\n      \"Inflammatory process (unlikely given mass characteristics and biopsy)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Wilms Tumor (Stage II)\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 52,
      "timestamp": "2026-01-10T20:11:37.644380"
    },
    {
      "sample_idx": 53,
      "input": "05/01/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 05/01/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"Reactive lymphadenopathy secondary to viral infection\",\n      \"Node size decreasing on follow-up\",\n      \"No atypical features\",\n      \"No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"Alternative Explanations\": [\n      \"Viral infection causing reactive lymphadenopathy\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy?\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 53,
      "timestamp": "2026-01-10T20:11:37.644399"
    },
    {
      "sample_idx": 54,
      "input": "23/03/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Bone pain. Suspected Hepatoblastoma.\n\nFrom clinical notes: Hepatoblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous hepatic mass with elevated AFP. Fetal histology subtype. PRETEXT stage II. Recommend MDT discussion and treatment planning.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 23/03/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": \"YES\",\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Clinical notes explicitly state 'Hepatoblastoma'.\",\n      \"Paediatric oncology assessment confirms the context of a potential childhood cancer.\",\n      \"Imaging (X-RAY, although limited for liver masses, the report implies further imaging or clinical context led to this conclusion) shows a 'large heterogeneous hepatic mass'.\",\n      \"Elevated AFP (Alpha-fetoprotein) is a known tumour marker strongly associated with Hepatoblastoma.\",\n      \"Histology subtype 'Fetal' is a recognized subtype of Hepatoblastoma.\",\n      \"PRETEXT staging (II) is a specific staging system used for Hepatoblastoma.\",\n      \"Recommendation for MDT (Multidisciplinary Team) discussion and treatment planning is standard practice for confirmed or highly suspected malignancies like Hepatoblastoma.\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": [\n      \"While the report strongly points to Hepatoblastoma, other rare paediatric liver tumours could theoretically present with a hepatic mass and elevated AFP, but the specific histological subtype and PRETEXT staging make Hepatoblastoma the most likely diagnosis based on the provided information.\"\n    ]\n  },\n  \"Final Diagnosis\": \"YES, Hepatoblastoma is confirmed based on clinical notes, imaging findings (hepatic mass), elevated AFP, specific histological subtype, and PRETEXT staging.\"\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 54,
      "timestamp": "2026-01-10T20:11:37.644432"
    },
    {
      "sample_idx": 55,
      "input": "31/08/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 31/08/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal chest radiograph\",\n      \"Clear lung fields\",\n      \"No mediastinal mass\",\n      \"Heart size normal\",\n      \"Explicit statement: No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign presentation (as stated in Case History)\",\n      \"Normal physiological state\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 55,
      "timestamp": "2026-01-10T20:11:37.644453"
    },
    {
      "sample_idx": 56,
      "input": "26/01/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 26/01/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reactive lymphadenopathy secondary to viral infection.\",\n      \"Node size decreasing on follow-up.\",\n      \"No atypical features.\",\n      \"No malignancy identified (explicitly stated).\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Viral infection causing reactive lymphadenopathy.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_or_revised\": \"CONFIRMED\",\n    \"diagnosis\": \"No malignancy identified. Findings consistent with reactive lymphadenopathy secondary to viral infection.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 56,
      "timestamp": "2026-01-10T20:11:37.644473"
    },
    {
      "sample_idx": 57,
      "input": "24/11/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Germ Cell Tumor.\n\nFrom clinical notes: Germ Cell Tumor. Paediatric oncology assessment.\n\nFindings: sacrococcygeal mass with mixed solid and cystic components. Elevated AFP and beta-hCG. Yolk sac tumor elements present. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 24/11/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Palpable mass\",\n      \"Suspected Germ Cell Tumor\",\n      \"Germ Cell Tumor (from clinical notes)\",\n      \"Paediatric oncology assessment\",\n      \"Sacrococcygeal mass with mixed solid and cystic components\",\n      \"Elevated AFP and beta-hCG (tumor markers associated with germ cell tumors)\",\n      \"Yolk sac tumor elements present (histological confirmation of malignancy)\"\n    ],\n    \"Findings Contradicting Malignancy\": [],\n    \"Alternative Explanations\": [\n      \"While the findings strongly point to malignancy, other conditions like benign teratomas or other types of masses could be considered, but the presence of yolk sac tumor elements and elevated tumor markers makes malignancy highly likely.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Conclusion\": \"Based on the presence of a sacrococcygeal mass, elevated tumor markers (AFP, beta-hCG), and histological evidence of yolk sac tumor elements, the diagnosis is malignant, specifically a Germ Cell Tumor (likely a Yolk Sac Tumor component). The paediatric oncology assessment further supports this conclusion.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 57,
      "timestamp": "2026-01-10T20:11:37.644505"
    },
    {
      "sample_idx": 58,
      "input": "01/01/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Unexplained fever and weight loss. Suspected Germ Cell Tumor.\n\nFrom clinical notes: Germ Cell Tumor. Paediatric oncology assessment.\n\nFindings: sacrococcygeal mass with mixed solid and cystic components. Elevated AFP and beta-hCG. Yolk sac tumor elements present. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 01/01/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Suspected Germ Cell Tumor\",\n      \"Paediatric oncology assessment\",\n      \"Sacrococcygeal mass with mixed solid and cystic components\",\n      \"Elevated AFP and beta-hCG\",\n      \"Yolk sac tumor elements present\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign germ cell tumor (e.g., teratoma)\",\n      \"Infection or inflammation causing mass and systemic symptoms\",\n      \"Other types of pediatric tumors\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Germ Cell Tumor, likely malignant (Yolk Sac Tumor elements present). Further characterization and staging required.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 58,
      "timestamp": "2026-01-10T20:11:37.644528"
    },
    {
      "sample_idx": 59,
      "input": "16/06/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Rhabdomyosarcoma.\n\nFrom clinical notes: Rhabdomyosarcoma. Paediatric oncology assessment.\n\nFindings: parameningeal mass with intracranial extension. Embryonal rhabdomyosarcoma on biopsy. PAX-FOXO1 fusion negative. Recommend MDT discussion and treatment planning.\n\nDr James Chen, Consultant Paediatric Oncologist 16/06/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Reason for Request: Pancytopenia (can be associated with bone marrow infiltration by malignancy).\",\n      \"Clinical notes: Rhabdomyosarcoma (a known malignancy).\",\n      \"Findings: parameningeal mass with intracranial extension (highly suggestive of malignancy, particularly a sarcoma).\",\n      \"Findings: Embryonal rhabdomyosarcoma on biopsy (definitive diagnosis of malignancy).\"\n    ],\n    \"Findings Contradicting Malignancy\": [],\n    \"Alternative Explanations\": [\n      \"Pancytopenia can have various causes other than malignancy (e.g., aplastic anemia, infections, autoimmune disorders, nutritional deficiencies). However, the biopsy result confirms malignancy.\",\n      \"Parameningeal masses can occasionally be benign, but in the context of suspected rhabdomyosarcoma and biopsy results, malignancy is confirmed.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed/Revised Assessment\": \"YES, malignancy is confirmed.\",\n    \"Diagnosis\": \"Embryonal Rhabdomyosarcoma\",\n    \"Additional Notes\": \"The report confirms a diagnosis of Embryonal Rhabdomyosarcoma, a malignant soft tissue sarcoma. The presence of a parameningeal mass with intracranial extension indicates advanced disease. The PAX-FOXO1 fusion negative status provides prognostic information. The pancytopenia is likely secondary to bone marrow involvement or treatment effects, although the report focuses on the biopsy findings.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 59,
      "timestamp": "2026-01-10T20:11:37.644562"
    },
    {
      "sample_idx": 60,
      "input": "08/05/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 08/05/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Reason for request: Rule out malignancy.\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"Normal brain MRI for age.\",\n      \"No mass lesion.\",\n      \"No abnormal enhancement.\",\n      \"Headaches attributed to migraine.\",\n      \"No malignancy identified.\",\n      \"Reassurance provided.\"\n    ],\n    \"Alternative Explanations\": [\n      \"Migraine headaches.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed or Revised Assessment\": \"NO malignancy identified. The patient's headaches are attributed to migraine, and the imaging findings are normal for age.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 60,
      "timestamp": "2026-01-10T20:11:37.644585"
    },
    {
      "sample_idx": 61,
      "input": "09/07/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Post-viral lymphocytosis. Atypical lymphocytes resolving. Monospot positive. EBV serology confirms. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 09/07/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Report explicitly states 'No malignancy identified'.\",\n      \"Findings are consistent with a post-viral process (lymphocytosis, atypical lymphocytes resolving, Monospot positive, EBV serology confirms).\",\n      \"Reassurance provided, suggesting a benign conclusion.\"\n    ],\n    \"contradicting_findings\": [\n      \"None found.\"\n    ],\n    \"alternative_explanations\": [\n      \"The findings strongly suggest infectious mononucleosis (glandular fever) caused by Epstein-Barr Virus (EBV), which is a benign, self-limiting illness.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\",\n    \"diagnosis\": \"Post-viral lymphocytosis, likely infectious mononucleosis (EBV infection). No evidence of malignancy.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 61,
      "timestamp": "2026-01-10T20:11:37.644608"
    },
    {
      "sample_idx": 62,
      "input": "08/05/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 08/05/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reactive lymphadenopathy secondary to viral infection.\",\n      \"Node size decreasing on follow-up.\",\n      \"No atypical features.\",\n      \"No malignancy identified.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Viral infection causing reactive lymphadenopathy.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_diagnosis\": \"NO malignancy identified. Findings consistent with reactive lymphadenopathy secondary to viral infection.\",\n    \"revised_assessment\": false\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 62,
      "timestamp": "2026-01-10T20:11:37.644631"
    },
    {
      "sample_idx": 63,
      "input": "04/12/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Resolved febrile illness. Blood counts normalized. No organomegaly. Clinical improvement noted. No malignancy identified. Reassurance provided.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 04/12/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Initial Assessment\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"Routine surveillance, no previous oncology history.\",\n      \"Resolved febrile illness.\",\n      \"Blood counts normalized.\",\n      \"No organomegaly.\",\n      \"Clinical improvement noted.\",\n      \"No malignancy identified (explicit statement).\"\n    ],\n    \"Alternative Explanations\": [\n      \"Resolved febrile illness (likely infectious or inflammatory, now resolved).\",\n      \"Normal physiological state post-illness.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"NO malignancy identified based on the provided report. The patient is undergoing routine surveillance following a resolved febrile illness with normalized blood counts and clinical improvement.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 63,
      "timestamp": "2026-01-10T20:11:37.644656"
    },
    {
      "sample_idx": 64,
      "input": "29/09/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 29/09/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"No malignancy identified.\",\n      \"Reactive lymphadenopathy secondary to viral infection.\",\n      \"Node size decreasing on follow-up.\",\n      \"No atypical features.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Viral infection causing reactive lymphadenopathy.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 64,
      "timestamp": "2026-01-10T20:11:37.644676"
    },
    {
      "sample_idx": 65,
      "input": "09/06/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Retinoblastoma.\n\nFrom clinical notes: Retinoblastoma. Paediatric oncology assessment.\n\nFindings: intraocular mass with calcifications. Bilateral disease. Family history positive. RB1 germline mutation detected. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 09/06/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Intraocular mass with calcifications\",\n      \"Bilateral disease\",\n      \"Family history positive\",\n      \"RB1 germline mutation detected\",\n      \"Clinical notes mention Retinoblastoma\",\n      \"Reason for request: Suspected Retinoblastoma\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While extremely rare, other intraocular masses could potentially present with calcifications, but the combination of bilateral disease, positive family history, and RB1 mutation strongly points away from alternatives.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"YES, malignancy is present. The findings are highly consistent with bilateral Retinoblastoma, supported by imaging characteristics (intraocular mass with calcifications), clinical presentation (bilateral disease), genetic testing (RB1 germline mutation), and family history.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 65,
      "timestamp": "2026-01-10T20:11:37.644704"
    },
    {
      "sample_idx": 66,
      "input": "16/05/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Neuroblastoma.\n\nFrom clinical notes: Neuroblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous suprarenal mass with calcifications. MIBG avidity present. Elevated urinary catecholamines. Stage III disease. Recommend MDT discussion and treatment planning.\n\nDr James Chen, Consultant Paediatric Oncologist 16/05/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": \"YES\",\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Large heterogeneous suprarenal mass with calcifications\",\n      \"MIBG avidity present\",\n      \"Elevated urinary catecholamines\",\n      \"Clinical suspicion of Neuroblastoma\",\n      \"Paediatric oncology assessment\",\n      \"Staging as Stage III disease\"\n    ],\n    \"Contradicting Findings\": [\n      \"None\"\n    ],\n    \"Alternative Explanations\": [\n      \"While other suprarenal masses exist, the combination of MIBG avidity, elevated catecholamines, calcifications, and clinical suspicion strongly points towards Neuroblastoma in a paediatric context.\"\n    ]\n  },\n  \"Final Diagnosis\": \"YES, Neuroblastoma\"\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 66,
      "timestamp": "2026-01-10T20:11:37.644727"
    },
    {
      "sample_idx": 67,
      "input": "21/03/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Normal CBC with age-appropriate values. No blast cells. Platelets adequate. Hemoglobin within normal limits. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 21/03/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"Normal CBC with age-appropriate values\",\n      \"No blast cells\",\n      \"Platelets adequate\",\n      \"Hemoglobin within normal limits\",\n      \"No malignancy identified (explicit statement)\"\n    ],\n    \"Alternative Explanations\": [\n      \"Follow-up post-treatment (implies previous condition, but report states no previous oncology history - requires clarification, but current findings are benign)\",\n      \"Routine check-up\",\n      \"Investigation for non-malignant condition\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed/Revised Assessment\": \"NO malignancy identified based on the provided report.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 67,
      "timestamp": "2026-01-10T20:11:37.644751"
    },
    {
      "sample_idx": 68,
      "input": "27/02/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Bone pain. Suspected Rhabdomyosarcoma.\n\nFrom clinical notes: Rhabdomyosarcoma. Paediatric oncology assessment.\n\nFindings: parameningeal mass with intracranial extension. Embryonal rhabdomyosarcoma on biopsy. PAX-FOXO1 fusion negative. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 27/02/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"malignancy_present\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Clinical suspicion of Rhabdomyosarcoma.\",\n      \"Biopsy confirms Embryonal rhabdomyosarcoma.\",\n      \"Presence of a parameningeal mass with intracranial extension.\"\n    ],\n    \"contradicting_findings\": [\n      \"PAX-FOXO1 fusion negative (this is a specific genetic marker often associated with Alveolar Rhabdomyosarcoma, its absence doesn't contradict Embryonal Rhabdomyosarcoma, but provides subtyping information).\"\n    ],\n    \"alternative_explanations\": [\n      \"While the biopsy confirms rhabdomyosarcoma, the specific subtype (Embryonal) is identified. Other diagnoses like other sarcomas or metastatic disease were considered but ruled out by the biopsy.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"malignancy_present\": \"YES\",\n    \"diagnosis\": \"Embryonal Rhabdomyosarcoma, parameningeal location with intracranial extension.\",\n    \"notes\": \"The PAX-FOXO1 fusion negative result helps refine the subtype to Embryonal Rhabdomyosarcoma, distinguishing it from Alveolar Rhabdomyosarcoma. Further MDT discussion is recommended for treatment planning.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 68,
      "timestamp": "2026-01-10T20:11:37.644784"
    },
    {
      "sample_idx": 69,
      "input": "16/10/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 16/10/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal chest radiograph.\",\n      \"Clear lung fields.\",\n      \"No mediastinal mass.\",\n      \"Heart size normal.\",\n      \"No malignancy identified (explicitly stated).\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"The reason for the request was 'Rule out malignancy', implying suspicion but no confirmed diagnosis.\",\n      \"The report is explicitly reassuring, suggesting the investigation was performed to exclude malignancy rather than confirm it.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 69,
      "timestamp": "2026-01-10T20:11:37.644808"
    },
    {
      "sample_idx": 70,
      "input": "29/11/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Unexplained fever and weight loss. Suspected Retinoblastoma.\n\nFrom clinical notes: Retinoblastoma. Paediatric oncology assessment.\n\nFindings: intraocular mass with calcifications. Bilateral disease. Family history positive. RB1 germline mutation detected. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 29/11/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": \"YES\",\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Intraocular mass with calcifications\",\n      \"Bilateral disease\",\n      \"Family history positive\",\n      \"RB1 germline mutation detected\",\n      \"Clinical suspicion of Retinoblastoma\",\n      \"Unexplained fever and weight loss (systemic symptoms often associated with malignancy)\"\n    ],\n    \"Contradicting Findings\": [\n      \"None\"\n    ],\n    \"Alternative Explanations\": [\n      \"Other rare intraocular tumours (e.g., endophthalmitis, Coats' disease), but the presence of calcifications, bilateral disease, positive family history, and confirmed RB1 mutation strongly points towards Retinoblastoma.\"\n    ]\n  },\n  \"Final Diagnosis\": \"YES, Retinoblastoma is highly likely, given the constellation of findings including clinical suspicion, imaging evidence (intraocular mass with calcifications, bilateral disease), positive family history, and genetic confirmation (RB1 germline mutation).\"\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 70,
      "timestamp": "2026-01-10T20:11:37.644837"
    },
    {
      "sample_idx": 71,
      "input": "11/10/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Hodgkin Lymphoma.\n\nFrom clinical notes: Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: mediastinal lymphadenopathy with bulky anterior mediastinal mass. PET-CT showing FDG-avid nodes. Classical Hodgkin, nodular sclerosing type. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 11/10/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Abnormal imaging. Suspected Hodgkin Lymphoma.\",\n      \"From clinical notes: Hodgkin Lymphoma.\",\n      \"Findings: mediastinal lymphadenopathy with bulky anterior mediastinal mass.\",\n      \"PET-CT showing FDG-avid nodes.\",\n      \"Classical Hodgkin, nodular sclerosing type.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While the report strongly suggests Hodgkin Lymphoma, other causes of mediastinal masses and lymphadenopathy (e.g., non-Hodgkin lymphoma, germ cell tumors, thymoma, infections like tuberculosis or fungal infections) should be considered, although the specific mention of 'Classical Hodgkin, nodular sclerosing type' makes lymphoma the most likely diagnosis.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_diagnosis\": \"YES\",\n    \"diagnosis_details\": \"Classical Hodgkin Lymphoma, nodular sclerosing type, based on clinical suspicion, imaging findings (mediastinal lymphadenopathy, bulky anterior mediastinal mass, FDG-avid nodes on PET-CT), and histological classification.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 71,
      "timestamp": "2026-01-10T20:11:37.644886"
    },
    {
      "sample_idx": 72,
      "input": "13/09/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Unexplained fever and weight loss. Suspected Rhabdomyosarcoma.\n\nFrom clinical notes: Rhabdomyosarcoma. Paediatric oncology assessment.\n\nFindings: parameningeal mass with intracranial extension. Embryonal rhabdomyosarcoma on biopsy. PAX-FOXO1 fusion negative. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 13/09/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Suspected Rhabdomyosarcoma in clinical notes.\",\n      \"Parameningeal mass with intracranial extension identified on PET-CT.\",\n      \"Biopsy confirmed Embryonal rhabdomyosarcoma.\",\n      \"Recommendation for MDT discussion and treatment planning, standard for malignancy.\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"PAX-FOXO1 fusion negative - While this is a specific genetic marker often associated with certain types of rhabdomyosarcoma (like alveolar), its absence doesn't rule out malignancy, especially embryonal type.\"\n    ],\n    \"Alternative Explanations\": [\n      \"While the biopsy confirms rhabdomyosarcoma, the negative PAX-FOXO1 fusion might initially raise questions about specific subtypes, but it's consistent with embryonal rhabdomyosarcoma. Other non-malignant conditions causing parameningeal masses are unlikely given the biopsy result.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Conclusion\": \"YES, malignancy is confirmed. The report clearly states a diagnosis of Embryonal rhabdomyosarcoma based on biopsy results, supported by imaging findings of a parameningeal mass with intracranial extension and clinical suspicion.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 72,
      "timestamp": "2026-01-10T20:11:37.644919"
    },
    {
      "sample_idx": 73,
      "input": "03/12/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Physiological splenomegaly for age. No focal lesions. Normal echo texture. Benign finding. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 03/12/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": \"NO\",\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"No focal lesions identified on ultrasound.\",\n      \"Normal echo texture of the spleen.\",\n      \"Benign finding noted.\",\n      \"Explicit statement: 'No malignancy identified'.\",\n      \"Reassurance provided by the consultant.\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": [\n      \"Physiological splenomegaly for age (a normal variant).\"\n    ]\n  },\n  \"Final Diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 73,
      "timestamp": "2026-01-10T20:11:37.644937"
    },
    {
      "sample_idx": 74,
      "input": "11/10/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Ewing Sarcoma.\n\nFrom clinical notes: Ewing Sarcoma. Paediatric oncology assessment.\n\nFindings: permeative bone destruction in left femoral diaphysis with large soft tissue mass. Onion-skin periosteal reaction. EWSR1 fusion positive. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 11/10/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings SUPPORTING malignancy\": [\n      \"Palpable mass\",\n      \"Suspected Ewing Sarcoma\",\n      \"Ewing Sarcoma mentioned in clinical notes\",\n      \"Permeative bone destruction in left femoral diaphysis\",\n      \"Large soft tissue mass\",\n      \"Onion-skin periosteal reaction\",\n      \"EWSR1 fusion positive\"\n    ],\n    \"Findings CONTRADICTING malignancy\": [],\n    \"Alternative Explanations\": [\n      \"Infection (osteomyelitis) can cause bone destruction and soft tissue mass, but EWSR1 fusion positivity is highly specific for Ewing Sarcoma.\",\n      \"Benign bone tumor (e.g., osteoid osteoma, giant cell tumor) can present as a mass, but permeative destruction and onion-skin reaction are more typical of malignancy. EWSR1 fusion positivity rules out most benign tumors.\",\n      \"Metastatic disease (less likely in pediatric population without known primary, but possible). EWSR1 fusion positivity points specifically to Ewing Sarcoma.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed or Revised Diagnosis\": \"Malignancy confirmed. The findings strongly support a diagnosis of Ewing Sarcoma, particularly given the specific EWSR1 fusion positivity, permeative bone destruction, onion-skin periosteal reaction, and soft tissue mass in a pediatric patient.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 74,
      "timestamp": "2026-01-10T20:11:37.644974"
    },
    {
      "sample_idx": 75,
      "input": "28/12/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 28/12/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Screening request with no previous oncology history.\",\n      \"Findings explicitly state 'Reactive lymphadenopathy secondary to viral infection'.\",\n      \"Node size is decreasing on follow-up, suggesting a resolving inflammatory process.\",\n      \"No atypical features were noted.\",\n      \"The report explicitly states 'No malignancy identified'.\",\n      \"Reassurance was provided, implying a benign finding.\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": [\n      \"Reactive lymphadenopathy secondary to viral infection (as stated in the report).\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy?\": \"NO\",\n    \"Justification\": \"The report definitively concludes 'No malignancy identified' and attributes the findings to reactive lymphadenopathy secondary to a viral infection, further supported by decreasing node size on follow-up.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 75,
      "timestamp": "2026-01-10T20:11:37.645003"
    },
    {
      "sample_idx": 76,
      "input": "02/05/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Normal CBC with age-appropriate values. No blast cells. Platelets adequate. Hemoglobin within normal limits. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 02/05/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal CBC with age-appropriate values.\",\n      \"No blast cells identified in CBC.\",\n      \"Platelets adequate.\",\n      \"Hemoglobin within normal limits.\",\n      \"Explicit statement: 'No malignancy identified'.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"The report explicitly states 'Benign presentation' as the reason for request, suggesting the initial concern was non-malignant.\",\n      \"The report provides reassurance, further supporting a benign finding.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 76,
      "timestamp": "2026-01-10T20:11:37.645027"
    },
    {
      "sample_idx": 77,
      "input": "06/10/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Healing fracture - normal process. No pathological features. Bone density normal. Trauma history consistent. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 06/10/2025, 00:00",
      "response": "```json\n{\n  \"step1_initial_assessment\": \"NO\",\n  \"step2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Healing fracture - normal process.\",\n      \"No pathological features.\",\n      \"Bone density normal.\",\n      \"Trauma history consistent.\",\n      \"No malignancy identified.\",\n      \"Reassurance provided.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"The findings are consistent with a benign healing fracture following trauma.\"\n    ]\n  },\n  \"step3_final_diagnosis\": \"NO\"\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 77,
      "timestamp": "2026-01-10T20:11:37.645048"
    },
    {
      "sample_idx": 78,
      "input": "27/02/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Acute Lymphoblastic Leukemia.\n\nFrom clinical notes: Acute Lymphoblastic Leukemia. Paediatric oncology assessment.\n\nFindings: bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells. Immunophenotyping consistent with B-cell ALL. CNS involvement negative. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 27/02/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells.\",\n      \"Immunophenotyping consistent with B-cell ALL.\",\n      \"Clinical suspicion of Acute Lymphoblastic Leukemia (ALL).\"\n    ],\n    \"contradicting_findings\": [\n      \"CNS involvement negative.\"\n    ],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest ALL, other hematological malignancies could present with bone marrow infiltration, although the immunophenotyping points specifically to B-cell ALL. The negative CNS involvement is a specific finding regarding disease spread, not an alternative diagnosis for the primary condition.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_diagnosis\": \"Acute Lymphoblastic Leukemia (ALL), B-cell type.\",\n    \"assessment_revision\": \"Initial assessment confirmed.\"\n  }\n}\n```\n\"\"\"\n```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Clinical suspicion of Acute Lymphoblastic Leukemia (ALL).\",\n      \"Bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells.\",\n      \"Immunophenotyping consistent with B-cell ALL.\"\n    ],\n    \"contradicting_findings\": [\n      \"CNS involvement negative.\"\n    ],\n    \"alternative_explanations\": [\n      \"The high percentage of lymphoblasts in the bone marrow is characteristic of leukemia. Immunophenotyping confirms the specific type (B-cell ALL). While other conditions can affect the bone marrow, the combination of findings strongly points to ALL. The negative CNS involvement indicates the absence of detectable disease spread to the central nervous system at this time, but does not contradict the diagnosis of ALL itself.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_diagnosis\": \"Acute Lymphoblastic Leukemia (ALL), B-cell type.\",\n    \"assessment_revision\": \"Initial assessment confirmed.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 78,
      "timestamp": "2026-01-10T20:11:37.645074"
    },
    {
      "sample_idx": 79,
      "input": "17/05/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Post-viral lymphocytosis. Atypical lymphocytes resolving. Monospot positive. EBV serology confirms. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 17/05/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy\": \"NO\"\n  },\n  \"Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"No malignancy identified.\",\n      \"Post-viral lymphocytosis.\",\n      \"Atypical lymphocytes resolving.\",\n      \"Monospot positive.\",\n      \"EBV serology confirms.\",\n      \"Reassurance provided.\"\n    ],\n    \"Alternative Explanations\": [\n      \"Infectious Mononucleosis (EBV infection)\",\n      \"Post-viral reactive process\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 79,
      "timestamp": "2026-01-10T20:11:37.645098"
    },
    {
      "sample_idx": 80,
      "input": "18/02/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Physiological splenomegaly for age. No focal lesions. Normal echo texture. Benign finding. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 18/02/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"malignancy_present\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"Benign presentation\",\n      \"No previous oncology history\",\n      \"No focal lesions\",\n      \"No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"alternative_explanations\": [\n      \"Physiological splenomegaly for age (benign finding)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"malignancy_present\": \"NO\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and describes the findings as 'Benign'. The patient has a benign presentation and no prior oncology history. The splenomegaly is noted as physiological for age, further supporting a benign process.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 80,
      "timestamp": "2026-01-10T20:11:37.645119"
    },
    {
      "sample_idx": 81,
      "input": "11/06/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Benign soft tissue mass - lipoma confirmed. Well-circumscribed. No enhancement. No intervention required. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 11/06/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"malignancy_present\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Benign soft tissue mass - lipoma confirmed.\",\n      \"Well-circumscribed.\",\n      \"No enhancement.\",\n      \"No malignancy identified.\",\n      \"Reassurance provided.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign soft tissue mass (lipoma)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"malignancy_present\": \"NO\",\n    \"diagnosis\": \"Benign lipoma of soft tissue\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 81,
      "timestamp": "2026-01-10T20:11:37.645140"
    },
    {
      "sample_idx": 82,
      "input": "27/12/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 27/12/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Abnormal imaging\",\n      \"Suspected Wilms Tumor\",\n      \"Clinical notes mention Wilms Tumor\",\n      \"Large heterogeneous left renal mass with pseudocapsule\",\n      \"Favorable histology on biopsy\",\n      \"Stage II diagnosis\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"No vascular invasion\"\n    ],\n    \"Alternative Explanations\": [\n      \"While the findings strongly suggest Wilms Tumor, other renal masses in children exist, though less likely given the specific description and clinical suspicion. However, the report explicitly states 'Wilms Tumor' and 'Favorable histology on biopsy', making alternatives less probable.\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy?\": \"YES\",\n    \"Diagnosis\": \"Wilms Tumor, Stage II, Favorable Histology\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 82,
      "timestamp": "2026-01-10T20:11:37.645166"
    },
    {
      "sample_idx": 83,
      "input": "05/11/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Osteosarcoma.\n\nFrom clinical notes: Osteosarcoma. Paediatric oncology assessment.\n\nFindings: destructive lesion in distal femur with soft tissue component. Sunburst periosteal reaction. Elevated alkaline phosphatase. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 05/11/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Palpable mass\",\n      \"Suspected Osteosarcoma\",\n      \"Clinical notes mention Osteosarcoma\",\n      \"Destructive lesion in distal femur with soft tissue component\",\n      \"Sunburst periosteal reaction\",\n      \"Elevated alkaline phosphatase\",\n      \"Recommendation for MDT discussion and treatment planning (typical for malignancy)\"\n    ],\n    \"contradicting_findings\": [\n      \"None explicitly stated in the report\"\n    ],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest Osteosarcoma, other bone malignancies (e.g., Ewing sarcoma) or even aggressive benign lesions could potentially present similarly, although less likely given the combination of findings.\",\n      \"Infection (osteomyelitis) can sometimes cause destructive lesions, but the 'sunburst periosteal reaction' is more characteristic of malignancy, particularly osteosarcoma.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"YES\",\n    \"justification\": \"The combination of a palpable mass, suspected and noted diagnosis of Osteosarcoma, a destructive bone lesion with a soft tissue component, a characteristic 'sunburst periosteal reaction', and elevated alkaline phosphatase strongly indicates a malignant bone tumor, consistent with Osteosarcoma. While other possibilities exist, the evidence overwhelmingly supports malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 83,
      "timestamp": "2026-01-10T20:11:37.645199"
    },
    {
      "sample_idx": 84,
      "input": "23/11/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Healing fracture - normal process. No pathological features. Bone density normal. Trauma history consistent. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 23/11/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Benign presentation\",\n      \"No previous oncology history\",\n      \"Healing fracture - normal process\",\n      \"No pathological features\",\n      \"Bone density normal\",\n      \"Trauma history consistent\",\n      \"No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Healing fracture due to trauma\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 84,
      "timestamp": "2026-01-10T20:11:37.645220"
    },
    {
      "sample_idx": 85,
      "input": "14/05/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 14/05/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal chest radiograph\",\n      \"Clear lung fields\",\n      \"No mediastinal mass\",\n      \"Heart size normal\",\n      \"Explicit statement: 'No malignancy identified'\",\n      \"Reassurance provided\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Routine surveillance (implies no current symptoms or suspicion)\",\n      \"Patient is paediatric (context from oncologist's title, although not directly related to findings)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 85,
      "timestamp": "2026-01-10T20:11:37.645239"
    },
    {
      "sample_idx": 86,
      "input": "11/06/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Hepatoblastoma.\n\nFrom clinical notes: Hepatoblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous hepatic mass with elevated AFP. Fetal histology subtype. PRETEXT stage II. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 11/06/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Pancytopenia (can be associated with malignancy)\",\n      \"Suspected Hepatoblastoma (explicit suspicion)\",\n      \"Clinical notes: Hepatoblastoma (explicit mention)\",\n      \"Findings: large heterogeneous hepatic mass (highly suspicious for tumor)\",\n      \"Findings: elevated AFP (tumor marker associated with Hepatoblastoma)\",\n      \"Findings: Fetal histology subtype (specific subtype of Hepatoblastoma)\",\n      \"Findings: PRETEXT stage II (staging system for Hepatoblastoma)\",\n      \"Recommendation: MDT discussion and treatment planning (standard for malignancy)\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign liver tumor (less likely given AFP, histology, and staging)\",\n      \"Metastatic disease to the liver (less likely given primary suspicion of Hepatoblastoma)\",\n      \"Inflammatory or infectious process (less likely given mass characteristics and AFP)\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"YES\",\n    \"reasoning\": \"The report explicitly mentions 'Hepatoblastoma' in both the reason for request and clinical notes. The findings of a large heterogeneous hepatic mass, elevated AFP, specific fetal histology subtype, and PRETEXT staging strongly support the diagnosis of Hepatoblastoma, a malignant liver tumor common in children. While alternative explanations exist, they are less likely given the comprehensive evidence presented.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 86,
      "timestamp": "2026-01-10T20:11:37.645275"
    },
    {
      "sample_idx": 87,
      "input": "16/12/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Acute Myeloid Leukemia.\n\nFrom clinical notes: Acute Myeloid Leukemia. Paediatric oncology assessment.\n\nFindings: myeloblasts accounting for 70% of marrow cellularity. Cytogenetic analysis reveals t(8;21) translocation. Favorable risk category. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 16/12/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Clinical suspicion of Acute Myeloid Leukemia (AML) noted in case history and clinical notes.\",\n      \"Bone marrow findings show myeloblasts accounting for 70% of marrow cellularity. A blast count of 20% or more in the bone marrow is diagnostic for acute leukemia.\",\n      \"Cytogenetic analysis reveals t(8;21) translocation, a specific genetic abnormality strongly associated with AML.\"\n    ],\n    \"Contradicting Findings\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"Alternative Explanations\": [\n      \"While the findings strongly point to AML, other conditions causing high blast counts (e.g., myelodysplastic syndromes with blast excess) are technically possible but less likely given the specific t(8;21) translocation which is characteristic of AML.\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Conclusion\": \"YES, malignancy is present. The findings are highly consistent with Acute Myeloid Leukemia (AML), specifically a subtype associated with the t(8;21) translocation, classified as favorable risk.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 87,
      "timestamp": "2026-01-10T20:11:37.645310"
    },
    {
      "sample_idx": 88,
      "input": "29/05/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr James Chen, Consultant Paediatric Oncologist 29/05/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Suspected Wilms Tumor\",\n      \"Wilms Tumor mentioned in clinical notes\",\n      \"Large heterogeneous left renal mass with pseudocapsule found\",\n      \"Favorable histology on biopsy\",\n      \"Stage II classification\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Pancytopenia could be related to other conditions, but the context points towards Wilms Tumor.\",\n      \"While a large renal mass is found, other benign renal tumors exist, but the histology suggests malignancy.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_malignancy\": \"YES\",\n    \"diagnosis_details\": \"Wilms Tumor, Stage II, favorable histology.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 88,
      "timestamp": "2026-01-10T20:11:37.645332"
    },
    {
      "sample_idx": 89,
      "input": "16/01/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Acute Lymphoblastic Leukemia.\n\nFrom clinical notes: Acute Lymphoblastic Leukemia. Paediatric oncology assessment.\n\nFindings: bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells. Immunophenotyping consistent with B-cell ALL. CNS involvement negative. Recommend MDT discussion and treatment planning.\n\nDr James Chen, Consultant Paediatric Oncologist 16/01/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells.\",\n      \"Immunophenotyping consistent with B-cell ALL.\",\n      \"Clinical suspicion of Acute Lymphoblastic Leukemia (ALL) based on palpable mass and paediatric oncology assessment.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest ALL, other haematological malignancies or reactive processes with atypical lymphoid proliferation could be considered, although the high percentage of lymphoblasts and specific immunophenotyping make these less likely.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Acute Lymphoblastic Leukemia (ALL), B-cell lineage\",\n    \"justification\": \"The report explicitly states bone marrow infiltration with 85% lymphoblasts, consistent with immunophenotyping for B-cell ALL. This meets the diagnostic criteria for ALL. The clinical suspicion and paediatric context further support this diagnosis.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 89,
      "timestamp": "2026-01-10T20:11:37.645361"
    },
    {
      "sample_idx": 90,
      "input": "06/09/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Retinoblastoma.\n\nFrom clinical notes: Retinoblastoma. Paediatric oncology assessment.\n\nFindings: intraocular mass with calcifications. Bilateral disease. Family history positive. RB1 germline mutation detected. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 06/09/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Palpable mass\",\n      \"Suspected Retinoblastoma\",\n      \"Clinical notes confirm Retinoblastoma\",\n      \"Intraocular mass with calcifications\",\n      \"Bilateral disease\",\n      \"Family history positive\",\n      \"RB1 germline mutation detected\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": []\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy\": \"YES\",\n    \"Diagnosis\": \"Retinoblastoma\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 90,
      "timestamp": "2026-01-10T20:11:37.645381"
    },
    {
      "sample_idx": 91,
      "input": "30/01/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Healing fracture - normal process. No pathological features. Bone density normal. Trauma history consistent. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 30/01/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"malignancy_present\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Benign presentation.\",\n      \"No previous oncology history.\",\n      \"Findings: Healing fracture - normal process.\",\n      \"No pathological features.\",\n      \"No malignancy identified.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Healing fracture due to trauma.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"malignancy_present\": \"NO\",\n    \"diagnosis\": \"Healing fracture, benign process. No evidence of malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 91,
      "timestamp": "2026-01-10T20:11:37.645402"
    },
    {
      "sample_idx": 92,
      "input": "22/05/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Benign bone cyst - resolved. No aggressive features. Normal bone density. No recurrence on imaging. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 22/05/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"No malignancy identified.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign bone cyst - resolved.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"NO malignancy identified. The patient's previous benign bone cyst has resolved, and there is no evidence of malignancy on the bone marrow biopsy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 92,
      "timestamp": "2026-01-10T20:11:37.645420"
    },
    {
      "sample_idx": 93,
      "input": "04/02/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Healing fracture - normal process. No pathological features. Bone density normal. Trauma history consistent. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 04/02/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"No malignancy identified.\",\n      \"No pathological features.\",\n      \"Healing fracture - normal process.\"\n    ],\n    \"alternative_explanations\": [\n      \"Trauma history consistent with healing fracture.\",\n      \"Normal bone density.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 93,
      "timestamp": "2026-01-10T20:11:37.645437"
    },
    {
      "sample_idx": 94,
      "input": "05/08/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 05/08/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal brain MRI for age.\",\n      \"No mass lesion identified.\",\n      \"No abnormal enhancement observed.\",\n      \"Explicit statement: 'No malignancy identified.'\",\n      \"Reassurance provided to the patient.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Headaches attributed to migraine.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"diagnosis\": \"No malignancy identified.\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and details findings consistent with a normal brain MRI (no mass lesion, no abnormal enhancement). The headaches are attributed to migraines, providing an alternative explanation for the presenting symptom.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 94,
      "timestamp": "2026-01-10T20:11:37.645463"
    },
    {
      "sample_idx": 95,
      "input": "10/03/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Healing fracture - normal process. No pathological features. Bone density normal. Trauma history consistent. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 10/03/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"No malignancy identified.\",\n      \"No pathological features.\",\n      \"Healing fracture - normal process.\",\n      \"Trauma history consistent.\"\n    ],\n    \"alternative_explanations\": [\n      \"Healing fracture due to trauma.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 95,
      "timestamp": "2026-01-10T20:11:37.645480"
    },
    {
      "sample_idx": 96,
      "input": "28/09/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Hodgkin Lymphoma.\n\nFrom clinical notes: Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: mediastinal lymphadenopathy with bulky anterior mediastinal mass. PET-CT showing FDG-avid nodes. Classical Hodgkin, nodular sclerosing type. Recommend MDT discussion and treatment planning.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 28/09/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Palpable mass noted clinically.\",\n      \"Suspected Hodgkin Lymphoma mentioned in the reason for request.\",\n      \"Clinical notes explicitly state Hodgkin Lymphoma.\",\n      \"Ultrasound findings: mediastinal lymphadenopathy with bulky anterior mediastinal mass.\",\n      \"PET-CT findings: FDG-avid nodes (suggestive of metabolic activity often seen in malignancy).\",\n      \"Histological classification: Classical Hodgkin, nodular sclerosing type (confirms lymphoma subtype).\"\n    ],\n    \"Contradicting Findings\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"Alternative Explanations\": [\n      \"While the report strongly points to Hodgkin Lymphoma, other causes of mediastinal masses and lymphadenopathy (e.g., infections like tuberculosis, other lymphomas, thymoma, germ cell tumors) should theoretically be considered, although the clinical suspicion and specific histological type make Hodgkin Lymphoma the most likely diagnosis.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Conclusion\": \"The diagnosis of Hodgkin Lymphoma, specifically Classical Hodgkin, nodular sclerosing type, is confirmed based on clinical suspicion, imaging findings (ultrasound, PET-CT), and histological classification. The report strongly supports the presence of malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 96,
      "timestamp": "2026-01-10T20:11:37.645516"
    },
    {
      "sample_idx": 97,
      "input": "02/01/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Bone pain. Suspected Brain Tumor - Glioma.\n\nFrom clinical notes: Brain Tumor - Glioma. Paediatric oncology assessment.\n\nFindings: left temporal lobe infiltrative mass with mass effect. FLAIR hyperintensity. Biopsy confirms diffuse astrocytoma WHO grade II. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 02/01/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Initial Assessment\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Clinical suspicion of Brain Tumor - Glioma.\",\n      \"Imaging (X-RAY - although MRI/CT would be typical for brain tumors) shows 'left temporal lobe infiltrative mass with mass effect'.\",\n      \"FLAIR hyperintensity on imaging suggests abnormality.\",\n      \"Biopsy confirms 'diffuse astrocytoma WHO grade II'.\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"Alternative Explanations\": [\n      \"While the report confirms a diagnosis, the term 'infiltrative mass' could potentially describe other conditions, but the biopsy result strongly points towards malignancy.\",\n      \"The mention of 'X-RAY' for a suspected brain tumor is unusual; MRI or CT are standard. This might be a data entry error or refer to a different study not detailed here, but it doesn't contradict the core findings.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"YES, the report confirms a diagnosis of diffuse astrocytoma WHO grade II, which is a type of malignant brain tumor.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 97,
      "timestamp": "2026-01-10T20:11:37.645547"
    },
    {
      "sample_idx": 98,
      "input": "29/06/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Normal CBC with age-appropriate values. No blast cells. Platelets adequate. Hemoglobin within normal limits. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 29/06/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy_present\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal CBC with age-appropriate values.\",\n      \"No blast cells identified.\",\n      \"Platelets adequate.\",\n      \"Hemoglobin within normal limits.\",\n      \"Explicit statement: 'No malignancy identified.'\",\n      \"Reassurance provided to the patient.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"The patient is undergoing follow-up post-treatment for a condition *other* than malignancy (e.g., infection, inflammation, benign lesion).\",\n      \"The patient had a previous concern for malignancy that has been ruled out.\",\n      \"The report is documenting a routine follow-up with no current suspicion of malignancy.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"final_assessment\": \"NO\",\n    \"justification\": \"The report explicitly states 'No malignancy identified' and provides supporting laboratory findings (Normal CBC, no blast cells, adequate platelets, normal hemoglobin). The context is a follow-up post-treatment, but the report itself does not indicate the treatment was for malignancy. Therefore, based on the provided information, malignancy is not currently identified.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 98,
      "timestamp": "2026-01-10T20:11:37.645579"
    },
    {
      "sample_idx": 99,
      "input": "21/03/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Hodgkin Lymphoma.\n\nFrom clinical notes: Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: mediastinal lymphadenopathy with bulky anterior mediastinal mass. PET-CT showing FDG-avid nodes. Classical Hodgkin, nodular sclerosing type. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 21/03/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Suspected Hodgkin Lymphoma in clinical notes.\",\n      \"Mediastinal lymphadenopathy with bulky anterior mediastinal mass.\",\n      \"FDG-avid nodes on PET-CT.\",\n      \"Classical Hodgkin, nodular sclerosing type confirmed.\",\n      \"Recommendation for MDT discussion and treatment planning.\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": []\n  },\n  \"Final Diagnosis\": {\n    \"Conclusion\": \"YES, the report confirms the presence of Classical Hodgkin Lymphoma, nodular sclerosing type, based on clinical suspicion, imaging findings (mediastinal mass, FDG-avid nodes), and histological classification.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 99,
      "timestamp": "2026-01-10T20:11:37.645605"
    }
  ],
  "num_samples": 100,
  "samples": [
    {
      "sample_idx": 0,
      "input": "02/01/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Resolved febrile illness. Blood counts normalized. No organomegaly. Clinical improvement noted. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 02/01/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": \"NO\",\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Benign presentation\",\n      \"No previous oncology history\",\n      \"Resolved febrile illness\",\n      \"Blood counts normalized\",\n      \"No organomegaly\",\n      \"Clinical improvement noted\",\n      \"No malignancy identified\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": [\n      \"The initial reason for the PET-CT scan is not specified, but the report indicates a benign process or a resolved condition.\",\n      \"The febrile illness could have been infectious or inflammatory, now resolved.\"\n    ]\n  },\n  \"Final Diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 0,
      "timestamp": "2026-01-10T20:11:37.642841"
    },
    {
      "sample_idx": 1,
      "input": "26/10/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Brain Tumor - Medulloblastoma.\n\nFrom clinical notes: Brain Tumor - Medulloblastoma. Paediatric oncology assessment.\n\nFindings: posterior fossa mass with enhancement and hydrocephalus. Restricted diffusion. High-grade medulloblastoma on histology. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 26/10/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Clinical suspicion of Brain Tumor - Medulloblastoma.\",\n      \"Paediatric oncology assessment context.\",\n      \"PET-CT findings: posterior fossa mass with enhancement.\",\n      \"PET-CT findings: hydrocephalus.\",\n      \"PET-CT findings: Restricted diffusion.\",\n      \"Histology: High-grade medulloblastoma.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest medulloblastoma, other posterior fossa tumors in children (e.g., ependymoma, atypical teratoid/rhabdoid tumor (AT/RT)) could present similarly, although histology confirmed medulloblastoma.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"YES, malignancy is present. The report confirms a high-grade medulloblastoma, a malignant brain tumor, based on clinical suspicion, imaging findings (posterior fossa mass with enhancement, hydrocephalus, restricted diffusion), and definitive histology.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 1,
      "timestamp": "2026-01-10T20:11:37.642903"
    },
    {
      "sample_idx": 2,
      "input": "03/07/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 03/07/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"None\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"Reactive lymphadenopathy secondary to viral infection.\",\n      \"Node size decreasing on follow-up.\",\n      \"No atypical features.\",\n      \"No malignancy identified.\"\n    ],\n    \"Alternative Explanations\": [\n      \"Viral infection causing reactive lymphadenopathy.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"NO malignancy identified. Findings are consistent with reactive lymphadenopathy secondary to a viral infection, which is improving.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 2,
      "timestamp": "2026-01-10T20:11:37.642932"
    },
    {
      "sample_idx": 3,
      "input": "27/02/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Non-Hodgkin Lymphoma.\n\nFrom clinical notes: Non-Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: abdominal lymphadenopathy with mesenteric and retroperitoneal nodes. Burkitt lymphoma confirmed on biopsy. High LDH levels. Recommend MDT discussion and treatment planning.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 27/02/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Palpable mass.\",\n      \"Suspected Non-Hodgkin Lymphoma.\",\n      \"Burkitt lymphoma confirmed on biopsy.\",\n      \"High LDH levels.\",\n      \"Abdominal lymphadenopathy with mesenteric and retroperitoneal nodes.\"\n    ],\n    \"Findings Contradicting Malignancy\": [],\n    \"Alternative Explanations\": [\n      \"While Burkitt lymphoma is confirmed, the report mentions 'abdominal lymphadenopathy' which could potentially be caused by infections or inflammatory conditions, though the biopsy confirmation points strongly towards lymphoma.\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy?\": \"YES\",\n    \"Diagnosis\": \"Burkitt Lymphoma\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 3,
      "timestamp": "2026-01-10T20:11:37.642958"
    },
    {
      "sample_idx": 4,
      "input": "04/05/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Acute Lymphoblastic Leukemia.\n\nFrom clinical notes: Acute Lymphoblastic Leukemia. Paediatric oncology assessment.\n\nFindings: bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells. Immunophenotyping consistent with B-cell ALL. CNS involvement negative. Recommend MDT discussion and treatment planning.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 04/05/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Initial Assessment\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Reason for Request: Pancytopenia (often associated with bone marrow infiltration by leukemia).\",\n      \"Clinical notes explicitly state: Acute Lymphoblastic Leukemia.\",\n      \"Ultrasound findings: bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells (high percentage strongly indicative of leukemia).\",\n      \"Immunophenotyping consistent with B-cell ALL (confirms the specific type of leukemia).\"\n    ],\n    \"Contradicting Findings\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"Alternative Explanations\": [\n      \"While pancytopenia can have other causes, the bone marrow findings and clinical suspicion strongly point towards ALL.\",\n      \"Other causes of bone marrow infiltration (e.g., metastatic solid tumors, other hematologic malignancies) are less likely given the specific findings of lymphoblasts and B-cell ALL immunophenotype.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"YES, the report confirms the diagnosis of Acute Lymphoblastic Leukemia (ALL), specifically B-cell ALL, based on clinical suspicion, pancytopenia, and definitive bone marrow findings showing significant lymphoblast infiltration and characteristic immunophenotyping.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 4,
      "timestamp": "2026-01-10T20:11:37.642994"
    },
    {
      "sample_idx": 5,
      "input": "17/09/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 17/09/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"No malignancy identified.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Reactive lymphadenopathy secondary to viral infection.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"NO malignancy identified. The findings are consistent with reactive lymphadenopathy likely due to a viral infection, which is resolving as indicated by decreasing node size on follow-up.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 5,
      "timestamp": "2026-01-10T20:11:37.643014"
    },
    {
      "sample_idx": 6,
      "input": "11/07/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Lymphadenopathy. Suspected Neuroblastoma.\n\nFrom clinical notes: Neuroblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous suprarenal mass with calcifications. MIBG avidity present. Elevated urinary catecholamines. Stage III disease. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 11/07/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Large heterogeneous suprarenal mass\",\n      \"Calcifications within the mass\",\n      \"MIBG avidity (characteristic of neuroblastoma)\",\n      \"Elevated urinary catecholamines (characteristic of neuroblastoma)\",\n      \"Clinical suspicion of Neuroblastoma\",\n      \"Staging as Stage III disease (implies malignancy and spread)\",\n      \"Recommendation for MDT discussion and treatment planning (standard for malignancy)\"\n    ],\n    \"contradicting_findings\": [\n      \"None explicitly stated in the report\"\n    ],\n    \"alternative_explanations\": [\n      \"While other adrenal masses exist (e.g., adrenal hemorrhage, benign tumors), the combination of findings (heterogeneity, calcifications, MIBG avidity, elevated catecholamines) strongly points towards neuroblastoma, making alternatives less likely in this context.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_malignancy\": \"YES\",\n    \"diagnosis\": \"Neuroblastoma (Stage III)\",\n    \"rationale\": \"The report explicitly mentions suspected and likely Neuroblastoma, supported by characteristic imaging findings (suprarenal mass with calcifications, MIBG avidity) and biochemical evidence (elevated catecholamines). The staging as Stage III further confirms a malignant process. There are no findings presented that contradict this diagnosis.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 6,
      "timestamp": "2026-01-10T20:11:37.643051"
    },
    {
      "sample_idx": 7,
      "input": "21/03/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 21/03/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"Normal chest radiograph\",\n      \"Clear lung fields\",\n      \"No mediastinal mass\",\n      \"Heart size normal\",\n      \"No malignancy identified (explicit statement)\",\n      \"Reassurance provided\"\n    ],\n    \"alternative_explanations\": [\n      \"Benign condition causing symptoms (reason for request not specified)\",\n      \"Normal findings (if symptoms were vague or non-specific)\",\n      \"False negative (though unlikely given the explicit statement and normal findings)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 7,
      "timestamp": "2026-01-10T20:11:37.643085"
    },
    {
      "sample_idx": 8,
      "input": "08/02/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Normal CBC with age-appropriate values. No blast cells. Platelets adequate. Hemoglobin within normal limits. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 08/02/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal CBC with age-appropriate values.\",\n      \"No blast cells identified.\",\n      \"Platelets adequate.\",\n      \"Hemoglobin within normal limits.\",\n      \"Explicit statement: No malignancy identified.\",\n      \"Reassurance provided to the patient/family.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"The reason for request 'Rule out malignancy' suggests a clinical suspicion, but the findings do not support it.\",\n      \"The normal findings could indicate a benign condition or no significant pathology.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO\"\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 8,
      "timestamp": "2026-01-10T20:11:37.643108"
    },
    {
      "sample_idx": 9,
      "input": "25/04/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 25/04/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"malignancy_present\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Large heterogeneous left renal mass with pseudocapsule.\",\n      \"Suspected Wilms Tumor.\",\n      \"Wilms Tumor mentioned in clinical notes.\",\n      \"Favorable histology on biopsy.\",\n      \"Stage II classification.\",\n      \"Recommendation for MDT discussion and treatment planning (standard for malignancy).\"\n    ],\n    \"contradicting_findings\": [\n      \"None\"\n    ],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest Wilms Tumor, other pediatric renal masses (e.g., clear cell sarcoma of the kidney, rhabdoid tumor of the kidney) are possible, though less likely given the 'favorable histology' noted.\",\n      \"Pancytopenia could be related to the tumor, bone marrow involvement, or treatment effects, but is not directly contradictory to the tumor diagnosis.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"malignancy_present\": \"YES\",\n    \"diagnosis\": \"Wilms Tumor (Stage II, favorable histology)\",\n    \"justification\": \"The report explicitly mentions a suspected and clinically noted Wilms Tumor, supported by imaging findings of a large heterogeneous left renal mass, a biopsy confirming favorable histology, and staging as Stage II. The recommendation for MDT discussion further supports a malignant diagnosis requiring specialized care.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 9,
      "timestamp": "2026-01-10T20:11:37.643144"
    },
    {
      "sample_idx": 10,
      "input": "26/12/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Hodgkin Lymphoma.\n\nFrom clinical notes: Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: mediastinal lymphadenopathy with bulky anterior mediastinal mass. PET-CT showing FDG-avid nodes. Classical Hodgkin, nodular sclerosing type. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 26/12/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Pancytopenia (can be associated with lymphoma)\",\n      \"From clinical notes: Hodgkin Lymphoma (explicit clinical suspicion)\",\n      \"Findings: mediastinal lymphadenopathy with bulky anterior mediastinal mass (common presentation of Hodgkin Lymphoma)\",\n      \"PET-CT showing FDG-avid nodes (suggestive of malignancy, particularly lymphoma)\",\n      \"Classical Hodgkin, nodular sclerosing type (specific diagnosis of Hodgkin Lymphoma)\"\n    ],\n    \"contradicting_findings\": [\n      \"None explicitly stated in the provided report.\"\n    ],\n    \"alternative_explanations\": [\n      \"While the findings strongly point to Hodgkin Lymphoma, other causes of mediastinal masses and lymphadenopathy (e.g., infections like tuberculosis, other lymphomas, thymoma, germ cell tumors) should be considered, although less likely given the specific diagnosis provided.\",\n      \"Pancytopenia can have various causes, but in this context, it's likely related to the suspected lymphoma.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Classical Hodgkin Lymphoma, nodular sclerosing type\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 10,
      "timestamp": "2026-01-10T20:11:37.643179"
    },
    {
      "sample_idx": 11,
      "input": "18/09/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Neuroblastoma.\n\nFrom clinical notes: Neuroblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous suprarenal mass with calcifications. MIBG avidity present. Elevated urinary catecholamines. Stage III disease. Recommend MDT discussion and treatment planning.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 18/09/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Large heterogeneous suprarenal mass with calcifications\",\n      \"MIBG avidity present\",\n      \"Elevated urinary catecholamines\",\n      \"Clinical suspicion of Neuroblastoma\",\n      \"Staging indicates Stage III disease (suggestive of malignancy)\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While highly suggestive of neuroblastoma, other suprarenal masses (e.g., adrenal cortical carcinoma, pheochromocytoma - though less likely in this age group given context) could theoretically present similarly, but the combination of MIBG avidity and elevated catecholamines strongly points towards neuroblastoma.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Neuroblastoma (Stage III)\",\n    \"justification\": \"The presence of a large, heterogeneous suprarenal mass with calcifications, combined with MIBG avidity and elevated urinary catecholamines, in the context of clinical suspicion and paediatric oncology assessment, strongly supports the diagnosis of Neuroblastoma. The staging as Stage III further confirms a malignant process requiring oncological management.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 11,
      "timestamp": "2026-01-10T20:11:37.643212"
    },
    {
      "sample_idx": 12,
      "input": "15/12/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Hepatoblastoma.\n\nFrom clinical notes: Hepatoblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous hepatic mass with elevated AFP. Fetal histology subtype. PRETEXT stage II. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 15/12/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Pancytopenia (can be associated with malignancy)\",\n      \"Suspected Hepatoblastoma (a malignant liver tumor)\",\n      \"Clinical notes mention Hepatoblastoma\",\n      \"Findings: large heterogeneous hepatic mass (characteristic of tumor)\",\n      \"Findings: elevated AFP (Alpha-fetoprotein, a common tumor marker for Hepatoblastoma)\",\n      \"Findings: Fetal histology subtype (specific type of Hepatoblastoma)\",\n      \"Findings: PRETEXT stage II (staging system for Hepatoblastoma, indicating malignancy)\",\n      \"Recommendation: MDT discussion and treatment planning (standard for malignancy)\"\n    ],\n    \"contradicting_findings\": [\n      \"None\"\n    ],\n    \"alternative_explanations\": [\n      \"While pancytopenia can have other causes (e.g., infection, autoimmune disease, bone marrow failure), the context strongly points towards malignancy.\",\n      \"Other liver masses exist, but the combination of findings (AFP elevation, specific histology, staging) is highly suggestive of Hepatoblastoma.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_assessment\": \"YES\",\n    \"diagnosis_summary\": \"The report strongly indicates the presence of Hepatoblastoma, a malignant liver tumor, based on the clinical suspicion, imaging findings (large heterogeneous hepatic mass), elevated tumor marker (AFP), histological subtype (fetal), and staging (PRETEXT II).\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 12,
      "timestamp": "2026-01-10T20:11:37.643250"
    },
    {
      "sample_idx": 13,
      "input": "26/02/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Langerhans Cell Histiocytosis.\n\nFrom clinical notes: Langerhans Cell Histiocytosis. Paediatric oncology assessment.\n\nFindings: multiple lytic skull lesions with soft tissue component. CD1a and Langerin positive. Multisystem disease. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 26/02/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": \"NO\",\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Multiple lytic skull lesions with soft tissue component.\",\n      \"CD1a and Langerin positive.\",\n      \"Multisystem disease.\",\n      \"Clinical suspicion of Langerhans Cell Histiocytosis (LCH).\"\n    ],\n    \"Contradicting Findings\": [\n      \"The report explicitly states Langerhans Cell Histiocytosis (LCH), not malignancy.\"\n    ],\n    \"Alternative Explanations\": [\n      \"Langerhans Cell Histiocytosis (LCH) is a non-malignant disorder characterized by the proliferation of Langerhans cells. While it can behave aggressively and involve multiple systems, it is not typically classified as a primary malignancy in the same way as leukemia or lymphoma. The findings are consistent with LCH.\"\n    ]\n  },\n  \"Final Diagnosis\": \"NO\"\n}\n```\n",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 13,
      "timestamp": "2026-01-10T20:11:37.643277"
    },
    {
      "sample_idx": 14,
      "input": "08/09/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Post-viral lymphocytosis. Atypical lymphocytes resolving. Monospot positive. EBV serology confirms. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 08/09/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"Screening reason for request (suggests concern, but not confirmed malignancy)\",\n      \"Post-viral lymphocytosis with atypical lymphocytes resolving\",\n      \"Monospot positive\",\n      \"EBV serology confirms (Epstein-Barr Virus, associated with infectious mononucleosis)\",\n      \"Explicit statement: No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"alternative_explanations\": [\n      \"Infectious mononucleosis (given positive Monospot and EBV serology)\",\n      \"Reactive lymphocytosis secondary to viral infection\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\",\n    \"diagnosis\": \"No malignancy identified. Findings consistent with resolving infectious mononucleosis (EBV infection).\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 14,
      "timestamp": "2026-01-10T20:11:37.643302"
    },
    {
      "sample_idx": 15,
      "input": "14/07/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Bone pain. Suspected Acute Myeloid Leukemia.\n\nFrom clinical notes: Acute Myeloid Leukemia. Paediatric oncology assessment.\n\nFindings: myeloblasts accounting for 70% of marrow cellularity. Cytogenetic analysis reveals t(8;21) translocation. Favorable risk category. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 14/07/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"myeloblasts accounting for 70% of marrow cellularity (normal is typically <5%)\",\n      \"Cytogenetic analysis reveals t(8;21) translocation (a specific chromosomal abnormality strongly associated with Acute Myeloid Leukemia)\",\n      \"Clinical suspicion of Acute Myeloid Leukemia (AML)\",\n      \"Paediatric oncology assessment context (AML is a known paediatric malignancy)\"\n    ],\n    \"Contradicting Findings\": [\n      \"None\"\n    ],\n    \"Alternative Explanations\": [\n      \"While bone pain can have other causes, the high percentage of myeloblasts and specific translocation strongly point towards AML.\",\n      \"Other bone marrow disorders could theoretically cause increased blasts, but the specific t(8;21) translocation is highly characteristic of AML.\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Confirmed Diagnosis\": \"Acute Myeloid Leukemia (AML) with t(8;21) translocation\",\n    \"Rationale\": \"The bone marrow biopsy showing 70% myeloblasts, combined with the specific t(8;21) translocation, confirms the diagnosis of Acute Myeloid Leukemia. This finding aligns with the clinical suspicion and paediatric oncology context.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 15,
      "timestamp": "2026-01-10T20:11:37.643339"
    },
    {
      "sample_idx": 16,
      "input": "07/10/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Unexplained fever and weight loss. Suspected Rhabdomyosarcoma.\n\nFrom clinical notes: Rhabdomyosarcoma. Paediatric oncology assessment.\n\nFindings: parameningeal mass with intracranial extension. Embryonal rhabdomyosarcoma on biopsy. PAX-FOXO1 fusion negative. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 07/10/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Clinical suspicion of Rhabdomyosarcoma.\",\n      \"Biopsy confirms Embryonal rhabdomyosarcoma.\",\n      \"Presence of a parameningeal mass with intracranial extension, consistent with aggressive behaviour often seen in rhabdomyosarcoma.\"\n    ],\n    \"contradicting_findings\": [\n      \"PAX-FOXO1 fusion negative. While this fusion is common in alveolar rhabdomyosarcoma, its absence doesn't rule out embryonal rhabdomyosarcoma, which is the diagnosed subtype here. It's more a characteristic of a different subtype, not a contradiction to the overall diagnosis of malignancy.\"\n    ],\n    \"alternative_explanations\": [\n      \"While the biopsy confirms rhabdomyosarcoma, the initial symptoms (fever, weight loss) are non-specific and could be associated with various conditions (infection, autoimmune disease, other malignancies). However, the biopsy result provides a definitive diagnosis in this context.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Embryonal Rhabdomyosarcoma (parameningeal location with intracranial extension)\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 16,
      "timestamp": "2026-01-10T20:11:37.643372"
    },
    {
      "sample_idx": 17,
      "input": "06/04/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 06/04/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal chest radiograph\",\n      \"Clear lung fields\",\n      \"No mediastinal mass\",\n      \"Heart size normal\",\n      \"No malignancy identified (explicit statement)\",\n      \"Reassurance provided\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Screening procedure\",\n      \"No underlying pathology found\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_assessment\": \"NO\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and describes normal findings on chest radiograph, including clear lung fields and no mediastinal mass. The reason for the request was screening, and reassurance was provided, further supporting the absence of malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 17,
      "timestamp": "2026-01-10T20:11:37.643397"
    },
    {
      "sample_idx": 18,
      "input": "23/05/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Bone pain. Suspected Brain Tumor - Medulloblastoma.\n\nFrom clinical notes: Brain Tumor - Medulloblastoma. Paediatric oncology assessment.\n\nFindings: posterior fossa mass with enhancement and hydrocephalus. Restricted diffusion. High-grade medulloblastoma on histology. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 23/05/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Posterior fossa mass with enhancement\",\n      \"Hydrocephalus\",\n      \"Restricted diffusion (suggestive of high cellularity/cytotoxicity)\",\n      \"High-grade medulloblastoma on histology\",\n      \"Clinical suspicion of Medulloblastoma\",\n      \"Paediatric oncology assessment context\"\n    ],\n    \"contradicting_findings\": [\n      \"None\"\n    ],\n    \"alternative_explanations\": [\n      \"While other posterior fossa tumors exist (e.g., ependymoma, astrocytoma), the histology specifically identifies medulloblastoma.\",\n      \"Hydrocephalus can have non-malignant causes, but in the context of a posterior fossa mass, malignancy is highly likely.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis_details\": \"High-grade medulloblastoma located in the posterior fossa, causing hydrocephalus.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 18,
      "timestamp": "2026-01-10T20:11:37.643426"
    },
    {
      "sample_idx": 19,
      "input": "09/07/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Neuroblastoma.\n\nFrom clinical notes: Neuroblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous suprarenal mass with calcifications. MIBG avidity present. Elevated urinary catecholamines. Stage III disease. Recommend MDT discussion and treatment planning.\n\nDr James Chen, Consultant Paediatric Oncologist 09/07/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Large heterogeneous suprarenal mass\",\n      \"Calcifications within the mass\",\n      \"MIBG avidity\",\n      \"Elevated urinary catecholamines\",\n      \"Clinical suspicion of Neuroblastoma\",\n      \"Stage III disease designation\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While highly suggestive of Neuroblastoma, other suprarenal masses (e.g., adrenal cortical carcinoma, pheochromocytoma, ganglioneuroma) could theoretically present with some similar features, although the combination of findings strongly points towards Neuroblastoma.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"YES, malignancy is present. The findings are highly consistent with Neuroblastoma, a malignant tumor of the sympathetic nervous system commonly found in children, originating in the adrenal gland (suprarenal mass).\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 19,
      "timestamp": "2026-01-10T20:11:37.643456"
    },
    {
      "sample_idx": 20,
      "input": "18/08/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 18/08/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Reason for Request: Pancytopenia (can be associated with malignancy).\",\n      \"Clinical notes: Wilms Tumor (explicitly stated).\",\n      \"Findings: Large heterogeneous left renal mass (highly suspicious for tumor).\",\n      \"Findings: Favorable histology on biopsy (confirms malignancy, specifically Wilms Tumor).\",\n      \"Stage II (indicates malignancy has spread beyond the kidney but is still potentially curable).\"\n    ],\n    \"Contradicting Findings\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"Alternative Explanations\": [\n      \"While pancytopenia can have other causes (e.g., infection, autoimmune disease, bone marrow failure), the presence of a large renal mass and a biopsy confirming favorable histology strongly points towards Wilms Tumor as the primary cause in this context.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed Diagnosis\": \"YES, malignancy is present. The report confirms a diagnosis of Wilms Tumor, Stage II, based on clinical suspicion, imaging findings (large heterogeneous left renal mass), and biopsy results (favorable histology).\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 20,
      "timestamp": "2026-01-10T20:11:37.643490"
    },
    {
      "sample_idx": 21,
      "input": "13/03/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 13/03/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy\": \"NO\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"No previous oncology history\",\n      \"Normal brain MRI for age\",\n      \"No mass lesion identified\",\n      \"No abnormal enhancement\",\n      \"Explicit statement: No malignancy identified\",\n      \"Reassurance provided to patient\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": [\n      \"Headaches attributed to migraine (non-malignant cause)\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 21,
      "timestamp": "2026-01-10T20:11:37.643513"
    },
    {
      "sample_idx": 22,
      "input": "18/10/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 18/10/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Palpable mass\",\n      \"Suspected Wilms Tumor\",\n      \"Clinical notes mention Wilms Tumor\",\n      \"Large heterogeneous left renal mass\",\n      \"Favorable histology on biopsy\",\n      \"Stage II\"\n    ],\n    \"contradicting_findings\": [\n      \"No vascular invasion\"\n    ],\n    \"alternative_explanations\": [\n      \"Other pediatric renal tumors (e.g., clear cell sarcoma of the kidney, rhabdoid tumor of the kidney), although Wilms Tumor is strongly suspected and biopsy confirmed favorable histology.\",\n      \"Benign renal mass (less likely given the description and suspicion)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Wilms Tumor (Stage II, favorable histology)\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 22,
      "timestamp": "2026-01-10T20:11:37.643542"
    },
    {
      "sample_idx": 23,
      "input": "02/05/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 02/05/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy\": \"NO\"\n  },\n  \"Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"Normal brain MRI for age\",\n      \"No mass lesion\",\n      \"No abnormal enhancement\",\n      \"Headaches attributed to migraine\",\n      \"No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"Alternative Explanations\": [\n      \"Migraine headaches\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 23,
      "timestamp": "2026-01-10T20:11:37.643563"
    },
    {
      "sample_idx": 24,
      "input": "16/05/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 16/05/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"Normal brain MRI for age.\",\n      \"No mass lesion.\",\n      \"No abnormal enhancement.\",\n      \"No malignancy identified.\",\n      \"Reassurance provided.\"\n    ],\n    \"alternative_explanations\": [\n      \"Headaches attributed to migraine (a non-malignant condition).\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 24,
      "timestamp": "2026-01-10T20:11:37.643585"
    },
    {
      "sample_idx": 25,
      "input": "16/05/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Unexplained fever and weight loss. Suspected Ewing Sarcoma.\n\nFrom clinical notes: Ewing Sarcoma. Paediatric oncology assessment.\n\nFindings: permeative bone destruction in left femoral diaphysis with large soft tissue mass. Onion-skin periosteal reaction. EWSR1 fusion positive. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 16/05/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Unexplained fever and weight loss (constitutional symptoms often associated with malignancy)\",\n      \"Suspected Ewing Sarcoma (a known malignancy)\",\n      \"Permeative bone destruction (characteristic of aggressive bone lesions, including malignancy)\",\n      \"Large soft tissue mass (often associated with malignant bone tumours)\",\n      \"Onion-skin periosteal reaction (classic radiographic sign often seen in Ewing Sarcoma)\",\n      \"EWSR1 fusion positive (specific genetic marker strongly associated with Ewing Sarcoma)\"\n    ],\n    \"Findings Contradicting Malignancy\": [],\n    \"Alternative Explanations\": [\n      \"Infection (osteomyelitis) can cause bone destruction and periosteal reaction, but EWSR1 fusion positivity makes this highly unlikely.\",\n      \"Benign bone tumours (e.g., osteoid osteoma, giant cell tumour) are less likely given the permeative destruction, large soft tissue mass, onion-skin reaction, and EWSR1 fusion.\",\n      \"Metastatic disease (less common in this age group without a known primary, but possible).\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Conclusion\": \"YES, malignancy is present. The findings are highly consistent with Ewing Sarcoma.\",\n    \"Justification\": \"The combination of clinical suspicion (Ewing Sarcoma), characteristic radiographic findings (permeative destruction, soft tissue mass, onion-skin periosteal reaction), and the specific genetic marker (EWSR1 fusion positivity) strongly confirms the presence of Ewing Sarcoma, a malignant bone tumour.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 25,
      "timestamp": "2026-01-10T20:11:37.643625"
    },
    {
      "sample_idx": 26,
      "input": "13/08/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Non-Hodgkin Lymphoma.\n\nFrom clinical notes: Non-Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: abdominal lymphadenopathy with mesenteric and retroperitoneal nodes. Burkitt lymphoma confirmed on biopsy. High LDH levels. Recommend MDT discussion and treatment planning.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 13/08/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Suspected Non-Hodgkin Lymphoma\",\n      \"Burkitt lymphoma confirmed on biopsy\",\n      \"Abdominal lymphadenopathy (mesenteric and retroperitoneal nodes)\",\n      \"High LDH levels (often associated with high cell turnover in lymphomas)\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"None explicitly stated in the report\"\n    ],\n    \"Alternative Explanations\": [\n      \"While the report confirms Burkitt lymphoma, the initial presentation was pancytopenia and suspected Non-Hodgkin Lymphoma. Pancytopenia can have other causes (e.g., aplastic anemia, infections, autoimmune disorders), but the biopsy confirmation points strongly towards lymphoma as the underlying cause in this case.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed Diagnosis\": \"Burkitt lymphoma\",\n    \"Assessment Revision\": \"Initial suspicion of Non-Hodgkin Lymphoma was confirmed as Burkitt lymphoma via biopsy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 26,
      "timestamp": "2026-01-10T20:11:37.643656"
    },
    {
      "sample_idx": 27,
      "input": "25/06/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Healing fracture - normal process. No pathological features. Bone density normal. Trauma history consistent. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 25/06/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings SUPPORTING malignancy\": [],\n    \"Findings CONTRADICTING malignancy\": [\n      \"No malignancy identified.\",\n      \"Healing fracture - normal process.\",\n      \"No pathological features.\",\n      \"Bone density normal.\",\n      \"Trauma history consistent.\"\n    ],\n    \"Alternative Explanations\": [\n      \"Healing fracture from trauma (non-malignant).\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Conclusion\": \"NO malignancy identified. The findings are consistent with a healing fracture from trauma, a normal process without pathological features.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 27,
      "timestamp": "2026-01-10T20:11:37.643678"
    },
    {
      "sample_idx": 28,
      "input": "01/07/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Benign bone cyst - resolved. No aggressive features. Normal bone density. No recurrence on imaging. No malignancy identified. Reassurance provided.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 01/07/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Benign bone cyst - resolved\",\n      \"No aggressive features\",\n      \"Normal bone density\",\n      \"No recurrence on imaging\",\n      \"No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Resolved benign bone cyst (as stated)\",\n      \"Normal bone findings\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and describes findings consistent with a resolved benign condition ('Benign bone cyst - resolved') with no aggressive features or recurrence. The reassurance provided further supports the absence of malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 28,
      "timestamp": "2026-01-10T20:11:37.643703"
    },
    {
      "sample_idx": 29,
      "input": "04/12/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Neuroblastoma.\n\nFrom clinical notes: Neuroblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous suprarenal mass with calcifications. MIBG avidity present. Elevated urinary catecholamines. Stage III disease. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 04/12/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Palpable mass\",\n      \"Suspected Neuroblastoma\",\n      \"Clinical notes mention Neuroblastoma\",\n      \"Large heterogeneous suprarenal mass with calcifications on PET-CT\",\n      \"MIBG avidity present on PET-CT\",\n      \"Elevated urinary catecholamines\",\n      \"Stage III disease designation\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Other adrenal masses (e.g., adrenal cortical carcinoma, ganglioneuroma, pheochromocytoma), though less likely given the combination of MIBG avidity, elevated catecholamines, and clinical suspicion.\",\n      \"Inflammatory or infectious process causing a mass (less likely given heterogeneity, calcifications, and MIBG avidity).\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Neuroblastoma, Stage III\",\n    \"reasoning\": \"The report strongly indicates malignancy, specifically Neuroblastoma. The presence of a large, heterogeneous suprarenal mass with calcifications, MIBG avidity (characteristic of neuroblastic tumors), elevated urinary catecholamines, and the clinical suspicion/designation of Neuroblastoma and Stage III disease collectively point towards a malignant diagnosis.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 29,
      "timestamp": "2026-01-10T20:11:37.643743"
    },
    {
      "sample_idx": 30,
      "input": "15/07/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Lymphadenopathy. Suspected Brain Tumor - Medulloblastoma.\n\nFrom clinical notes: Brain Tumor - Medulloblastoma. Paediatric oncology assessment.\n\nFindings: posterior fossa mass with enhancement and hydrocephalus. Restricted diffusion. High-grade medulloblastoma on histology. Recommend MDT discussion and treatment planning.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 15/07/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Posterior fossa mass with enhancement\",\n      \"Hydrocephalus (often associated with brain tumors)\",\n      \"Restricted diffusion (suggestive of high cellularity, common in high-grade tumors)\",\n      \"High-grade medulloblastoma on histology (definitive confirmation of malignancy)\",\n      \"Clinical suspicion of Medulloblastoma\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While hydrocephalus can have other causes, the presence of a posterior fossa mass makes a tumor the most likely cause.\",\n      \"Other posterior fossa tumors could be considered, but histology confirms medulloblastoma.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"High-grade Medulloblastoma\"\n  }\n}\n```\n\"\"\"\n```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Clinical suspicion of Brain Tumor - Medulloblastoma\",\n      \"Posterior fossa mass with enhancement\",\n      \"Hydrocephalus\",\n      \"Restricted diffusion\",\n      \"High-grade medulloblastoma on histology\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Hydrocephalus can have non-tumor causes, but is likely secondary to the mass.\",\n      \"Other posterior fossa masses exist, but histology confirms medulloblastoma.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"High-grade Medulloblastoma\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 30,
      "timestamp": "2026-01-10T20:11:37.643770"
    },
    {
      "sample_idx": 31,
      "input": "02/04/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 02/04/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal chest radiograph.\",\n      \"Clear lung fields.\",\n      \"No mediastinal mass.\",\n      \"Heart size normal.\",\n      \"Explicit statement: 'No malignancy identified.'\",\n      \"Reason for Request: Benign presentation.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign presentation as stated in the history.\",\n      \"Normal physiological findings.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\",\n    \"summary\": \"Based on the normal chest X-ray findings and the explicit statement by the consulting paediatric oncologist, there is no evidence of malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 31,
      "timestamp": "2026-01-10T20:11:37.643792"
    },
    {
      "sample_idx": 32,
      "input": "04/10/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Germ Cell Tumor.\n\nFrom clinical notes: Germ Cell Tumor. Paediatric oncology assessment.\n\nFindings: sacrococcygeal mass with mixed solid and cystic components. Elevated AFP and beta-hCG. Yolk sac tumor elements present. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 04/10/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Palpable mass\",\n      \"Suspected Germ Cell Tumor\",\n      \"Clinical notes mention Germ Cell Tumor\",\n      \"Sacrococcygeal mass with mixed solid and cystic components\",\n      \"Elevated AFP (Alpha-fetoprotein)\",\n      \"Elevated beta-hCG (beta-human chorionic gonadotropin)\",\n      \"Yolk sac tumor elements present\",\n      \"Recommendation for MDT (Multidisciplinary Team) discussion and treatment planning\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest malignancy, other rare sacrococcygeal masses (e.g., teratomas, other benign cystic lesions) could be considered, although less likely given the specific tumor markers and histology mentioned.\",\n      \"Inflammatory or infectious processes could cause masses, but the specific tumor markers (AFP, beta-hCG) and histology (yolk sac elements) make these highly improbable.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_diagnosis\": \"YES\",\n    \"diagnosis_details\": \"The report strongly indicates a malignant Germ Cell Tumor, specifically with Yolk Sac Tumor elements, based on the presence of a sacrococcygeal mass, elevated tumor markers (AFP, beta-hCG), and histological findings. The recommendation for MDT discussion further supports the need for treatment planning for a likely malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 32,
      "timestamp": "2026-01-10T20:11:37.643828"
    },
    {
      "sample_idx": 33,
      "input": "24/11/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Hodgkin Lymphoma.\n\nFrom clinical notes: Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: mediastinal lymphadenopathy with bulky anterior mediastinal mass. PET-CT showing FDG-avid nodes. Classical Hodgkin, nodular sclerosing type. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 24/11/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Palpable mass\",\n      \"Suspected Hodgkin Lymphoma\",\n      \"Clinical notes mention Hodgkin Lymphoma\",\n      \"Mediastinal lymphadenopathy\",\n      \"Bulky anterior mediastinal mass\",\n      \"PET-CT showing FDG-avid nodes\",\n      \"Classical Hodgkin, nodular sclerosing type (histological confirmation implied)\",\n      \"Recommendation for MDT discussion and treatment planning (standard for malignancy)\"\n    ],\n    \"contradicting_findings\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"alternative_explanations\": [\n      \"While the report strongly suggests Hodgkin Lymphoma, other causes of mediastinal mass and lymphadenopathy exist (e.g., infection, other lymphomas, germ cell tumors, thymoma). However, the specific mention of 'Classical Hodgkin, nodular sclerosing type' strongly points towards this diagnosis.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Classical Hodgkin Lymphoma, nodular sclerosing type\",\n    \"confidence\": \"High\",\n    \"justification\": \"The report explicitly states 'Hodgkin Lymphoma' in the clinical notes and confirms 'Classical Hodgkin, nodular sclerosing type'. Imaging findings (mediastinal lymphadenopathy, bulky mass, FDG-avid nodes) are consistent with lymphoma. The recommendation for MDT discussion further supports a malignant diagnosis requiring specialized care.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 33,
      "timestamp": "2026-01-10T20:11:37.643878"
    },
    {
      "sample_idx": 34,
      "input": "07/03/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Normal CBC with age-appropriate values. No blast cells. Platelets adequate. Hemoglobin within normal limits. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 07/03/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"Normal CBC with age-appropriate values.\",\n      \"No blast cells identified.\",\n      \"Platelets adequate.\",\n      \"Hemoglobin within normal limits.\",\n      \"Explicit statement: 'No malignancy identified.'\"\n    ],\n    \"Alternative Explanations\": [\n      \"Routine surveillance finding.\",\n      \"Normal bone marrow findings.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed/Revised Diagnosis\": \"NO malignancy identified. The report indicates normal bone marrow findings consistent with routine surveillance.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 34,
      "timestamp": "2026-01-10T20:11:37.643901"
    },
    {
      "sample_idx": 35,
      "input": "04/10/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Benign soft tissue mass - lipoma confirmed. Well-circumscribed. No enhancement. No intervention required. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 04/10/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Report explicitly states 'No malignancy identified'.\",\n      \"Findings describe a 'Benign soft tissue mass - lipoma confirmed'.\",\n      \"The mass is described as 'Well-circumscribed' and shows 'No enhancement', features typically associated with benign lesions.\",\n      \"The report concludes with 'Reassurance provided' and 'No intervention required'.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"The finding is a benign lipoma, a common type of fatty tumor.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\",\n    \"conclusion\": \"The report definitively concludes that no malignancy was identified, and the finding is a benign lipoma.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 35,
      "timestamp": "2026-01-10T20:11:37.643926"
    },
    {
      "sample_idx": 36,
      "input": "04/01/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 04/01/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy_present\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal chest radiograph.\",\n      \"Clear lung fields.\",\n      \"No mediastinal mass.\",\n      \"Heart size normal.\",\n      \"No malignancy identified (explicitly stated).\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Screening procedure, potentially for underlying condition or risk factor, but no malignancy found.\",\n      \"False negative (although unlikely given the explicit statement and normal findings).\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"final_assessment\": \"NO\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and describes normal findings on the chest radiograph, including clear lung fields and no mediastinal mass. The biopsy was performed as a screening measure, and the results are reassuring.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 36,
      "timestamp": "2026-01-10T20:11:37.643955"
    },
    {
      "sample_idx": 37,
      "input": "02/04/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Osteosarcoma.\n\nFrom clinical notes: Osteosarcoma. Paediatric oncology assessment.\n\nFindings: destructive lesion in distal femur with soft tissue component. Sunburst periosteal reaction. Elevated alkaline phosphatase. Recommend MDT discussion and treatment planning.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 02/04/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Destructive lesion in distal femur with soft tissue component\",\n      \"Sunburst periosteal reaction\",\n      \"Elevated alkaline phosphatase (often associated with bone turnover, common in osteosarcoma)\",\n      \"Clinical suspicion of Osteosarcoma from clinical notes\",\n      \"Paediatric oncology assessment requested\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Ewing sarcoma (can also present with bone lesions and periosteal reaction)\",\n      \"Infection (osteomyelitis) (can cause destructive lesions, though sunburst reaction is less typical)\",\n      \"Metastatic disease (less likely in a paediatric patient without known primary)\",\n      \"Benign bone tumor (e.g., giant cell tumor, chondroblastoma) (less likely given the aggressive features described)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"assessment\": \"The findings strongly support the clinical suspicion of Osteosarcoma. The combination of a destructive bone lesion with a soft tissue component and a characteristic sunburst periosteal reaction in a paediatric patient is highly suggestive of malignancy, specifically osteosarcoma. Elevated alkaline phosphatase further supports this. While other diagnoses are possible, osteosarcoma is the most likely diagnosis based on the provided information.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 37,
      "timestamp": "2026-01-10T20:11:37.643992"
    },
    {
      "sample_idx": 38,
      "input": "05/03/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Lymphadenopathy. Suspected Osteosarcoma.\n\nFrom clinical notes: Osteosarcoma. Paediatric oncology assessment.\n\nFindings: destructive lesion in distal femur with soft tissue component. Sunburst periosteal reaction. Elevated alkaline phosphatase. Recommend MDT discussion and treatment planning.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 05/03/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Destructive lesion in distal femur with soft tissue component\",\n      \"Sunburst periosteal reaction\",\n      \"Clinical suspicion of Osteosarcoma\",\n      \"Elevated alkaline phosphatase (often associated with bone turnover/malignancy)\",\n      \"Paediatric oncology assessment context\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Infection (osteomyelitis) can sometimes present with destructive lesions and periosteal reaction, but the 'sunburst' pattern is highly suggestive of osteosarcoma.\",\n      \"Benign bone tumors (e.g., giant cell tumor, chondroblastoma) are less likely given the aggressive features described (destructive, soft tissue component, sunburst pattern).\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"assessment\": \"YES\",\n    \"reasoning\": \"The combination of a destructive bone lesion in the distal femur, a characteristic sunburst periosteal reaction, soft tissue involvement, elevated alkaline phosphatase, and the clinical suspicion strongly points towards a malignant bone tumor, highly likely Osteosarcoma, especially in the context of a paediatric oncology assessment.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 38,
      "timestamp": "2026-01-10T20:11:37.644028"
    },
    {
      "sample_idx": 39,
      "input": "01/11/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Post-viral lymphocytosis. Atypical lymphocytes resolving. Monospot positive. EBV serology confirms. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 01/11/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"No malignancy identified.\"\n    ],\n    \"alternative_explanations\": [\n      \"Post-viral lymphocytosis\",\n      \"Atypical lymphocytes resolving\",\n      \"Monospot positive\",\n      \"EBV serology confirms\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and provides alternative explanations consistent with a recent Epstein-Barr Virus (EBV) infection (infectious mononucleosis), including post-viral lymphocytosis, resolving atypical lymphocytes, a positive Monospot test, and confirmed EBV serology. The request was for screening in a patient with no previous oncology history, further reducing the likelihood of malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 39,
      "timestamp": "2026-01-10T20:11:37.644053"
    },
    {
      "sample_idx": 40,
      "input": "26/04/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 26/04/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Reason for Request: Pancytopenia (can be associated with bone marrow involvement by malignancy, although not directly indicative of the primary tumor).\",\n      \"From clinical notes: Wilms Tumor (explicitly states suspected/diagnosed Wilms Tumor, which is a malignancy).\",\n      \"Findings: large heterogeneous left renal mass with pseudocapsule (describes a suspicious mass, highly characteristic of Wilms Tumor).\",\n      \"Findings: Favorable histology on biopsy (confirms the mass is a Wilms Tumor, a malignancy, and indicates a better prognosis subtype).\",\n      \"Findings: Stage II (confirms the tumor is staged, implying a confirmed diagnosis of malignancy).\",\n      \"Recommend MDT discussion and treatment planning (standard procedure for confirmed malignancy).\"\n    ],\n    \"Contradicting Findings\": [\n      \"No vascular invasion (this is a favorable prognostic factor but does not contradict malignancy).\",\n      \"Pancytopenia (While potentially related to malignancy, it's non-specific and could have other causes. However, in the context of a suspected Wilms tumor, it raises concern for bone marrow involvement).\"\n    ],\n    \"Alternative Explanations\": [\n      \"Pancytopenia could be due to other causes (e.g., aplastic anemia, infection, autoimmune disease), but the clinical context strongly points towards Wilms Tumor.\",\n      \"The renal mass could theoretically be a benign tumor or inflammatory process, but the biopsy result ('Favorable histology on biopsy') confirms it as Wilms Tumor.\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy\": \"YES\",\n    \"Diagnosis\": \"Wilms Tumor (Stage II, Favorable Histology)\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 40,
      "timestamp": "2026-01-10T20:11:37.644094"
    },
    {
      "sample_idx": 41,
      "input": "18/11/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Lymphadenopathy. Suspected Hodgkin Lymphoma.\n\nFrom clinical notes: Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: mediastinal lymphadenopathy with bulky anterior mediastinal mass. PET-CT showing FDG-avid nodes. Classical Hodgkin, nodular sclerosing type. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 18/11/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Lymphadenopathy.\",\n      \"From clinical notes: Hodgkin Lymphoma.\",\n      \"Findings: mediastinal lymphadenopathy with bulky anterior mediastinal mass.\",\n      \"PET-CT showing FDG-avid nodes.\",\n      \"Classical Hodgkin, nodular sclerosing type.\",\n      \"Recommend MDT discussion and treatment planning.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": []\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_diagnosis\": \"YES, Hodgkin Lymphoma (Classical, nodular sclerosing type)\",\n    \"rationale\": \"The report explicitly states 'Hodgkin Lymphoma' in the clinical notes and confirms 'Classical Hodgkin, nodular sclerosing type' in the findings section. The presence of mediastinal lymphadenopathy, a bulky anterior mediastinal mass, and FDG-avid nodes on PET-CT are characteristic findings supporting this diagnosis. The recommendation for MDT discussion and treatment planning further reinforces the presence of a malignancy requiring intervention.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 41,
      "timestamp": "2026-01-10T20:11:37.644127"
    },
    {
      "sample_idx": 42,
      "input": "20/04/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Post-viral lymphocytosis. Atypical lymphocytes resolving. Monospot positive. EBV serology confirms. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 20/04/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"No malignancy identified.\"\n    ],\n    \"alternative_explanations\": [\n      \"Post-viral lymphocytosis\",\n      \"Atypical lymphocytes resolving\",\n      \"Monospot positive\",\n      \"EBV serology confirms (Infectious Mononucleosis)\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 42,
      "timestamp": "2026-01-10T20:11:37.644144"
    },
    {
      "sample_idx": 43,
      "input": "20/01/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 20/01/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Initial Assessment\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"Normal brain MRI for age\",\n      \"No mass lesion identified\",\n      \"No abnormal enhancement observed\",\n      \"Explicit statement: No malignancy identified\",\n      \"Reassurance provided to the patient\"\n    ],\n    \"Alternative Explanations\": [\n      \"Headaches attributed to migraine (a benign condition)\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 43,
      "timestamp": "2026-01-10T20:11:37.644163"
    },
    {
      "sample_idx": 44,
      "input": "22/11/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Ewing Sarcoma.\n\nFrom clinical notes: Ewing Sarcoma. Paediatric oncology assessment.\n\nFindings: permeative bone destruction in left femoral diaphysis with large soft tissue mass. Onion-skin periosteal reaction. EWSR1 fusion positive. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 22/11/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Permeative bone destruction in left femoral diaphysis\",\n      \"Large soft tissue mass\",\n      \"Onion-skin periosteal reaction\",\n      \"EWSR1 fusion positive\",\n      \"Clinical suspicion of Ewing Sarcoma\",\n      \"Paediatric oncology assessment context\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest Ewing Sarcoma, other bone malignancies (e.g., osteosarcoma, lymphoma) or even aggressive infections (osteomyelitis) could potentially present with some similar features, although the combination, especially the EWSR1 fusion, makes Ewing Sarcoma highly likely.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_or_revised_assessment\": \"YES\",\n    \"diagnosis\": \"Ewing Sarcoma\",\n    \"justification\": \"The combination of permeative bone destruction, a large soft tissue mass, onion-skin periosteal reaction, and a positive EWSR1 fusion gene test in a paediatric patient with clinical suspicion strongly confirms the diagnosis of Ewing Sarcoma.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 44,
      "timestamp": "2026-01-10T20:11:37.644200"
    },
    {
      "sample_idx": 45,
      "input": "06/05/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 06/05/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"Normal brain MRI for age.\",\n      \"No mass lesion.\",\n      \"No abnormal enhancement.\",\n      \"No malignancy identified.\"\n    ],\n    \"alternative_explanations\": [\n      \"Headaches attributed to migraine.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 45,
      "timestamp": "2026-01-10T20:11:37.644217"
    },
    {
      "sample_idx": 46,
      "input": "24/10/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Physiological splenomegaly for age. No focal lesions. Normal echo texture. Benign finding. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 24/10/2025, 00:00",
      "response": "```json\n{\n  \"step1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"No focal lesions identified on X-ray.\",\n      \"Normal echo texture observed.\",\n      \"Report explicitly states 'Benign finding'.\",\n      \"Report explicitly states 'No malignancy identified'.\",\n      \"Reassurance provided to the patient.\"\n    ],\n    \"contradicting_findings\": [\n      \"Physiological splenomegaly for age.\"\n    ],\n    \"alternative_explanations\": [\n      \"Physiological splenomegaly is a common finding in children and adolescents and is not indicative of malignancy in this context.\",\n      \"The splenomegaly is described as 'physiological', meaning it's considered a normal variation for the patient's age.\"\n    ]\n  },\n  \"step3_final_diagnosis\": {\n    \"conclusion\": \"The initial assessment of NO malignancy is confirmed. The findings strongly support a benign condition, with the splenomegaly being attributed to physiological causes rather than malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 46,
      "timestamp": "2026-01-10T20:11:37.644247"
    },
    {
      "sample_idx": 47,
      "input": "01/02/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 01/02/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"No malignancy identified.\",\n      \"Reactive lymphadenopathy secondary to viral infection.\",\n      \"Node size decreasing on follow-up.\",\n      \"No atypical features.\"\n    ],\n    \"alternative_explanations\": [\n      \"Viral infection causing reactive lymphadenopathy.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 47,
      "timestamp": "2026-01-10T20:11:37.644264"
    },
    {
      "sample_idx": 48,
      "input": "03/10/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Lymphadenopathy. Suspected Osteosarcoma.\n\nFrom clinical notes: Osteosarcoma. Paediatric oncology assessment.\n\nFindings: destructive lesion in distal femur with soft tissue component. Sunburst periosteal reaction. Elevated alkaline phosphatase. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 03/10/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Initial Assessment\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Destructive lesion in distal femur with soft tissue component\",\n      \"Sunburst periosteal reaction\",\n      \"Elevated alkaline phosphatase\",\n      \"Clinical suspicion of Osteosarcoma\",\n      \"Paediatric oncology assessment context\"\n    ],\n    \"Contradicting Findings\": [\n      \"None explicitly stated in the report\"\n    ],\n    \"Alternative Explanations\": [\n      \"While Osteosarcoma is strongly suspected, other bone malignancies (e.g., Ewing sarcoma) or aggressive benign bone lesions could theoretically present with some similar features, although the 'sunburst' pattern is highly characteristic of Osteosarcoma.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"YES, highly suspicious for Osteosarcoma based on imaging findings and clinical context.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 48,
      "timestamp": "2026-01-10T20:11:37.644291"
    },
    {
      "sample_idx": 49,
      "input": "05/08/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 05/08/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reactive lymphadenopathy secondary to viral infection.\",\n      \"Node size decreasing on follow-up.\",\n      \"No atypical features.\",\n      \"No malignancy identified.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Viral infection causing reactive lymphadenopathy.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO malignancy identified. The findings are consistent with reactive lymphadenopathy secondary to a viral infection, which is resolving as indicated by decreasing node size.\"\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 49,
      "timestamp": "2026-01-10T20:11:37.644310"
    },
    {
      "sample_idx": 50,
      "input": "02/05/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 02/05/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Initial Assessment\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"Benign presentation\",\n      \"No previous oncology history\",\n      \"Normal chest radiograph\",\n      \"Clear lung fields\",\n      \"No mediastinal mass\",\n      \"Heart size normal\",\n      \"No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"Alternative Explanations\": [\n      \"Benign condition\",\n      \"Normal findings\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 50,
      "timestamp": "2026-01-10T20:11:37.644332"
    },
    {
      "sample_idx": 51,
      "input": "26/07/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Benign soft tissue mass - lipoma confirmed. Well-circumscribed. No enhancement. No intervention required. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 26/07/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Benign soft tissue mass - lipoma confirmed.\",\n      \"Well-circumscribed.\",\n      \"No enhancement.\",\n      \"No malignancy identified.\",\n      \"Reassurance provided.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign soft tissue mass (lipoma) as stated in the report.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"NO malignancy identified. The findings are consistent with a benign lipoma.\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and confirms the mass as a 'Benign soft tissue mass - lipoma'. Features like being 'Well-circumscribed' and having 'No enhancement' further support a benign nature.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 51,
      "timestamp": "2026-01-10T20:11:37.644358"
    },
    {
      "sample_idx": 52,
      "input": "25/03/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Bone pain. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 25/03/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Suspected Wilms Tumor\",\n      \"Wilms Tumor mentioned in clinical notes\",\n      \"Large heterogeneous left renal mass\",\n      \"Favorable histology on biopsy\",\n      \"Stage II diagnosis\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign renal tumor (less likely given biopsy and staging)\",\n      \"Inflammatory process (unlikely given mass characteristics and biopsy)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Wilms Tumor (Stage II)\"\n  }\n}\n```\n\"\"\"\n```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Bone pain. Suspected Wilms Tumor.\",\n      \"From clinical notes: Wilms Tumor. Paediatric oncology assessment.\",\n      \"Findings: large heterogeneous left renal mass with pseudocapsule.\",\n      \"Favorable histology on biopsy.\",\n      \"Stage II diagnosis.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign renal tumor (less likely given biopsy and staging)\",\n      \"Inflammatory process (unlikely given mass characteristics and biopsy)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Wilms Tumor (Stage II)\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 52,
      "timestamp": "2026-01-10T20:11:37.644380"
    },
    {
      "sample_idx": 53,
      "input": "05/01/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 05/01/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"Reactive lymphadenopathy secondary to viral infection\",\n      \"Node size decreasing on follow-up\",\n      \"No atypical features\",\n      \"No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"Alternative Explanations\": [\n      \"Viral infection causing reactive lymphadenopathy\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy?\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 53,
      "timestamp": "2026-01-10T20:11:37.644399"
    },
    {
      "sample_idx": 54,
      "input": "23/03/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Bone pain. Suspected Hepatoblastoma.\n\nFrom clinical notes: Hepatoblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous hepatic mass with elevated AFP. Fetal histology subtype. PRETEXT stage II. Recommend MDT discussion and treatment planning.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 23/03/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": \"YES\",\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Clinical notes explicitly state 'Hepatoblastoma'.\",\n      \"Paediatric oncology assessment confirms the context of a potential childhood cancer.\",\n      \"Imaging (X-RAY, although limited for liver masses, the report implies further imaging or clinical context led to this conclusion) shows a 'large heterogeneous hepatic mass'.\",\n      \"Elevated AFP (Alpha-fetoprotein) is a known tumour marker strongly associated with Hepatoblastoma.\",\n      \"Histology subtype 'Fetal' is a recognized subtype of Hepatoblastoma.\",\n      \"PRETEXT staging (II) is a specific staging system used for Hepatoblastoma.\",\n      \"Recommendation for MDT (Multidisciplinary Team) discussion and treatment planning is standard practice for confirmed or highly suspected malignancies like Hepatoblastoma.\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": [\n      \"While the report strongly points to Hepatoblastoma, other rare paediatric liver tumours could theoretically present with a hepatic mass and elevated AFP, but the specific histological subtype and PRETEXT staging make Hepatoblastoma the most likely diagnosis based on the provided information.\"\n    ]\n  },\n  \"Final Diagnosis\": \"YES, Hepatoblastoma is confirmed based on clinical notes, imaging findings (hepatic mass), elevated AFP, specific histological subtype, and PRETEXT staging.\"\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 54,
      "timestamp": "2026-01-10T20:11:37.644432"
    },
    {
      "sample_idx": 55,
      "input": "31/08/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 31/08/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal chest radiograph\",\n      \"Clear lung fields\",\n      \"No mediastinal mass\",\n      \"Heart size normal\",\n      \"Explicit statement: No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign presentation (as stated in Case History)\",\n      \"Normal physiological state\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 55,
      "timestamp": "2026-01-10T20:11:37.644453"
    },
    {
      "sample_idx": 56,
      "input": "26/01/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 26/01/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reactive lymphadenopathy secondary to viral infection.\",\n      \"Node size decreasing on follow-up.\",\n      \"No atypical features.\",\n      \"No malignancy identified (explicitly stated).\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Viral infection causing reactive lymphadenopathy.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_or_revised\": \"CONFIRMED\",\n    \"diagnosis\": \"No malignancy identified. Findings consistent with reactive lymphadenopathy secondary to viral infection.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 56,
      "timestamp": "2026-01-10T20:11:37.644473"
    },
    {
      "sample_idx": 57,
      "input": "24/11/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Germ Cell Tumor.\n\nFrom clinical notes: Germ Cell Tumor. Paediatric oncology assessment.\n\nFindings: sacrococcygeal mass with mixed solid and cystic components. Elevated AFP and beta-hCG. Yolk sac tumor elements present. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 24/11/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Palpable mass\",\n      \"Suspected Germ Cell Tumor\",\n      \"Germ Cell Tumor (from clinical notes)\",\n      \"Paediatric oncology assessment\",\n      \"Sacrococcygeal mass with mixed solid and cystic components\",\n      \"Elevated AFP and beta-hCG (tumor markers associated with germ cell tumors)\",\n      \"Yolk sac tumor elements present (histological confirmation of malignancy)\"\n    ],\n    \"Findings Contradicting Malignancy\": [],\n    \"Alternative Explanations\": [\n      \"While the findings strongly point to malignancy, other conditions like benign teratomas or other types of masses could be considered, but the presence of yolk sac tumor elements and elevated tumor markers makes malignancy highly likely.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Conclusion\": \"Based on the presence of a sacrococcygeal mass, elevated tumor markers (AFP, beta-hCG), and histological evidence of yolk sac tumor elements, the diagnosis is malignant, specifically a Germ Cell Tumor (likely a Yolk Sac Tumor component). The paediatric oncology assessment further supports this conclusion.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 57,
      "timestamp": "2026-01-10T20:11:37.644505"
    },
    {
      "sample_idx": 58,
      "input": "01/01/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Unexplained fever and weight loss. Suspected Germ Cell Tumor.\n\nFrom clinical notes: Germ Cell Tumor. Paediatric oncology assessment.\n\nFindings: sacrococcygeal mass with mixed solid and cystic components. Elevated AFP and beta-hCG. Yolk sac tumor elements present. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 01/01/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Suspected Germ Cell Tumor\",\n      \"Paediatric oncology assessment\",\n      \"Sacrococcygeal mass with mixed solid and cystic components\",\n      \"Elevated AFP and beta-hCG\",\n      \"Yolk sac tumor elements present\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign germ cell tumor (e.g., teratoma)\",\n      \"Infection or inflammation causing mass and systemic symptoms\",\n      \"Other types of pediatric tumors\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Germ Cell Tumor, likely malignant (Yolk Sac Tumor elements present). Further characterization and staging required.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 58,
      "timestamp": "2026-01-10T20:11:37.644528"
    },
    {
      "sample_idx": 59,
      "input": "16/06/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Rhabdomyosarcoma.\n\nFrom clinical notes: Rhabdomyosarcoma. Paediatric oncology assessment.\n\nFindings: parameningeal mass with intracranial extension. Embryonal rhabdomyosarcoma on biopsy. PAX-FOXO1 fusion negative. Recommend MDT discussion and treatment planning.\n\nDr James Chen, Consultant Paediatric Oncologist 16/06/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Reason for Request: Pancytopenia (can be associated with bone marrow infiltration by malignancy).\",\n      \"Clinical notes: Rhabdomyosarcoma (a known malignancy).\",\n      \"Findings: parameningeal mass with intracranial extension (highly suggestive of malignancy, particularly a sarcoma).\",\n      \"Findings: Embryonal rhabdomyosarcoma on biopsy (definitive diagnosis of malignancy).\"\n    ],\n    \"Findings Contradicting Malignancy\": [],\n    \"Alternative Explanations\": [\n      \"Pancytopenia can have various causes other than malignancy (e.g., aplastic anemia, infections, autoimmune disorders, nutritional deficiencies). However, the biopsy result confirms malignancy.\",\n      \"Parameningeal masses can occasionally be benign, but in the context of suspected rhabdomyosarcoma and biopsy results, malignancy is confirmed.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed/Revised Assessment\": \"YES, malignancy is confirmed.\",\n    \"Diagnosis\": \"Embryonal Rhabdomyosarcoma\",\n    \"Additional Notes\": \"The report confirms a diagnosis of Embryonal Rhabdomyosarcoma, a malignant soft tissue sarcoma. The presence of a parameningeal mass with intracranial extension indicates advanced disease. The PAX-FOXO1 fusion negative status provides prognostic information. The pancytopenia is likely secondary to bone marrow involvement or treatment effects, although the report focuses on the biopsy findings.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 59,
      "timestamp": "2026-01-10T20:11:37.644562"
    },
    {
      "sample_idx": 60,
      "input": "08/05/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 08/05/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Reason for request: Rule out malignancy.\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"Normal brain MRI for age.\",\n      \"No mass lesion.\",\n      \"No abnormal enhancement.\",\n      \"Headaches attributed to migraine.\",\n      \"No malignancy identified.\",\n      \"Reassurance provided.\"\n    ],\n    \"Alternative Explanations\": [\n      \"Migraine headaches.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed or Revised Assessment\": \"NO malignancy identified. The patient's headaches are attributed to migraine, and the imaging findings are normal for age.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 60,
      "timestamp": "2026-01-10T20:11:37.644585"
    },
    {
      "sample_idx": 61,
      "input": "09/07/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Post-viral lymphocytosis. Atypical lymphocytes resolving. Monospot positive. EBV serology confirms. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 09/07/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Report explicitly states 'No malignancy identified'.\",\n      \"Findings are consistent with a post-viral process (lymphocytosis, atypical lymphocytes resolving, Monospot positive, EBV serology confirms).\",\n      \"Reassurance provided, suggesting a benign conclusion.\"\n    ],\n    \"contradicting_findings\": [\n      \"None found.\"\n    ],\n    \"alternative_explanations\": [\n      \"The findings strongly suggest infectious mononucleosis (glandular fever) caused by Epstein-Barr Virus (EBV), which is a benign, self-limiting illness.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\",\n    \"diagnosis\": \"Post-viral lymphocytosis, likely infectious mononucleosis (EBV infection). No evidence of malignancy.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 61,
      "timestamp": "2026-01-10T20:11:37.644608"
    },
    {
      "sample_idx": 62,
      "input": "08/05/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 08/05/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reactive lymphadenopathy secondary to viral infection.\",\n      \"Node size decreasing on follow-up.\",\n      \"No atypical features.\",\n      \"No malignancy identified.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Viral infection causing reactive lymphadenopathy.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_diagnosis\": \"NO malignancy identified. Findings consistent with reactive lymphadenopathy secondary to viral infection.\",\n    \"revised_assessment\": false\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 62,
      "timestamp": "2026-01-10T20:11:37.644631"
    },
    {
      "sample_idx": 63,
      "input": "04/12/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Resolved febrile illness. Blood counts normalized. No organomegaly. Clinical improvement noted. No malignancy identified. Reassurance provided.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 04/12/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Initial Assessment\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"Routine surveillance, no previous oncology history.\",\n      \"Resolved febrile illness.\",\n      \"Blood counts normalized.\",\n      \"No organomegaly.\",\n      \"Clinical improvement noted.\",\n      \"No malignancy identified (explicit statement).\"\n    ],\n    \"Alternative Explanations\": [\n      \"Resolved febrile illness (likely infectious or inflammatory, now resolved).\",\n      \"Normal physiological state post-illness.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"NO malignancy identified based on the provided report. The patient is undergoing routine surveillance following a resolved febrile illness with normalized blood counts and clinical improvement.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 63,
      "timestamp": "2026-01-10T20:11:37.644656"
    },
    {
      "sample_idx": 64,
      "input": "29/09/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 29/09/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"No malignancy identified.\",\n      \"Reactive lymphadenopathy secondary to viral infection.\",\n      \"Node size decreasing on follow-up.\",\n      \"No atypical features.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Viral infection causing reactive lymphadenopathy.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 64,
      "timestamp": "2026-01-10T20:11:37.644676"
    },
    {
      "sample_idx": 65,
      "input": "09/06/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Retinoblastoma.\n\nFrom clinical notes: Retinoblastoma. Paediatric oncology assessment.\n\nFindings: intraocular mass with calcifications. Bilateral disease. Family history positive. RB1 germline mutation detected. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 09/06/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Intraocular mass with calcifications\",\n      \"Bilateral disease\",\n      \"Family history positive\",\n      \"RB1 germline mutation detected\",\n      \"Clinical notes mention Retinoblastoma\",\n      \"Reason for request: Suspected Retinoblastoma\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While extremely rare, other intraocular masses could potentially present with calcifications, but the combination of bilateral disease, positive family history, and RB1 mutation strongly points away from alternatives.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"YES, malignancy is present. The findings are highly consistent with bilateral Retinoblastoma, supported by imaging characteristics (intraocular mass with calcifications), clinical presentation (bilateral disease), genetic testing (RB1 germline mutation), and family history.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 65,
      "timestamp": "2026-01-10T20:11:37.644704"
    },
    {
      "sample_idx": 66,
      "input": "16/05/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Neuroblastoma.\n\nFrom clinical notes: Neuroblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous suprarenal mass with calcifications. MIBG avidity present. Elevated urinary catecholamines. Stage III disease. Recommend MDT discussion and treatment planning.\n\nDr James Chen, Consultant Paediatric Oncologist 16/05/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": \"YES\",\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Large heterogeneous suprarenal mass with calcifications\",\n      \"MIBG avidity present\",\n      \"Elevated urinary catecholamines\",\n      \"Clinical suspicion of Neuroblastoma\",\n      \"Paediatric oncology assessment\",\n      \"Staging as Stage III disease\"\n    ],\n    \"Contradicting Findings\": [\n      \"None\"\n    ],\n    \"Alternative Explanations\": [\n      \"While other suprarenal masses exist, the combination of MIBG avidity, elevated catecholamines, calcifications, and clinical suspicion strongly points towards Neuroblastoma in a paediatric context.\"\n    ]\n  },\n  \"Final Diagnosis\": \"YES, Neuroblastoma\"\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 66,
      "timestamp": "2026-01-10T20:11:37.644727"
    },
    {
      "sample_idx": 67,
      "input": "21/03/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Normal CBC with age-appropriate values. No blast cells. Platelets adequate. Hemoglobin within normal limits. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 21/03/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"Normal CBC with age-appropriate values\",\n      \"No blast cells\",\n      \"Platelets adequate\",\n      \"Hemoglobin within normal limits\",\n      \"No malignancy identified (explicit statement)\"\n    ],\n    \"Alternative Explanations\": [\n      \"Follow-up post-treatment (implies previous condition, but report states no previous oncology history - requires clarification, but current findings are benign)\",\n      \"Routine check-up\",\n      \"Investigation for non-malignant condition\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed/Revised Assessment\": \"NO malignancy identified based on the provided report.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 67,
      "timestamp": "2026-01-10T20:11:37.644751"
    },
    {
      "sample_idx": 68,
      "input": "27/02/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Bone pain. Suspected Rhabdomyosarcoma.\n\nFrom clinical notes: Rhabdomyosarcoma. Paediatric oncology assessment.\n\nFindings: parameningeal mass with intracranial extension. Embryonal rhabdomyosarcoma on biopsy. PAX-FOXO1 fusion negative. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 27/02/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"malignancy_present\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Clinical suspicion of Rhabdomyosarcoma.\",\n      \"Biopsy confirms Embryonal rhabdomyosarcoma.\",\n      \"Presence of a parameningeal mass with intracranial extension.\"\n    ],\n    \"contradicting_findings\": [\n      \"PAX-FOXO1 fusion negative (this is a specific genetic marker often associated with Alveolar Rhabdomyosarcoma, its absence doesn't contradict Embryonal Rhabdomyosarcoma, but provides subtyping information).\"\n    ],\n    \"alternative_explanations\": [\n      \"While the biopsy confirms rhabdomyosarcoma, the specific subtype (Embryonal) is identified. Other diagnoses like other sarcomas or metastatic disease were considered but ruled out by the biopsy.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"malignancy_present\": \"YES\",\n    \"diagnosis\": \"Embryonal Rhabdomyosarcoma, parameningeal location with intracranial extension.\",\n    \"notes\": \"The PAX-FOXO1 fusion negative result helps refine the subtype to Embryonal Rhabdomyosarcoma, distinguishing it from Alveolar Rhabdomyosarcoma. Further MDT discussion is recommended for treatment planning.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 68,
      "timestamp": "2026-01-10T20:11:37.644784"
    },
    {
      "sample_idx": 69,
      "input": "16/10/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 16/10/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal chest radiograph.\",\n      \"Clear lung fields.\",\n      \"No mediastinal mass.\",\n      \"Heart size normal.\",\n      \"No malignancy identified (explicitly stated).\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"The reason for the request was 'Rule out malignancy', implying suspicion but no confirmed diagnosis.\",\n      \"The report is explicitly reassuring, suggesting the investigation was performed to exclude malignancy rather than confirm it.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 69,
      "timestamp": "2026-01-10T20:11:37.644808"
    },
    {
      "sample_idx": 70,
      "input": "29/11/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Unexplained fever and weight loss. Suspected Retinoblastoma.\n\nFrom clinical notes: Retinoblastoma. Paediatric oncology assessment.\n\nFindings: intraocular mass with calcifications. Bilateral disease. Family history positive. RB1 germline mutation detected. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 29/11/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": \"YES\",\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Intraocular mass with calcifications\",\n      \"Bilateral disease\",\n      \"Family history positive\",\n      \"RB1 germline mutation detected\",\n      \"Clinical suspicion of Retinoblastoma\",\n      \"Unexplained fever and weight loss (systemic symptoms often associated with malignancy)\"\n    ],\n    \"Contradicting Findings\": [\n      \"None\"\n    ],\n    \"Alternative Explanations\": [\n      \"Other rare intraocular tumours (e.g., endophthalmitis, Coats' disease), but the presence of calcifications, bilateral disease, positive family history, and confirmed RB1 mutation strongly points towards Retinoblastoma.\"\n    ]\n  },\n  \"Final Diagnosis\": \"YES, Retinoblastoma is highly likely, given the constellation of findings including clinical suspicion, imaging evidence (intraocular mass with calcifications, bilateral disease), positive family history, and genetic confirmation (RB1 germline mutation).\"\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 70,
      "timestamp": "2026-01-10T20:11:37.644837"
    },
    {
      "sample_idx": 71,
      "input": "11/10/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Hodgkin Lymphoma.\n\nFrom clinical notes: Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: mediastinal lymphadenopathy with bulky anterior mediastinal mass. PET-CT showing FDG-avid nodes. Classical Hodgkin, nodular sclerosing type. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 11/10/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Abnormal imaging. Suspected Hodgkin Lymphoma.\",\n      \"From clinical notes: Hodgkin Lymphoma.\",\n      \"Findings: mediastinal lymphadenopathy with bulky anterior mediastinal mass.\",\n      \"PET-CT showing FDG-avid nodes.\",\n      \"Classical Hodgkin, nodular sclerosing type.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While the report strongly suggests Hodgkin Lymphoma, other causes of mediastinal masses and lymphadenopathy (e.g., non-Hodgkin lymphoma, germ cell tumors, thymoma, infections like tuberculosis or fungal infections) should be considered, although the specific mention of 'Classical Hodgkin, nodular sclerosing type' makes lymphoma the most likely diagnosis.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_diagnosis\": \"YES\",\n    \"diagnosis_details\": \"Classical Hodgkin Lymphoma, nodular sclerosing type, based on clinical suspicion, imaging findings (mediastinal lymphadenopathy, bulky anterior mediastinal mass, FDG-avid nodes on PET-CT), and histological classification.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 71,
      "timestamp": "2026-01-10T20:11:37.644886"
    },
    {
      "sample_idx": 72,
      "input": "13/09/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Unexplained fever and weight loss. Suspected Rhabdomyosarcoma.\n\nFrom clinical notes: Rhabdomyosarcoma. Paediatric oncology assessment.\n\nFindings: parameningeal mass with intracranial extension. Embryonal rhabdomyosarcoma on biopsy. PAX-FOXO1 fusion negative. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 13/09/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Suspected Rhabdomyosarcoma in clinical notes.\",\n      \"Parameningeal mass with intracranial extension identified on PET-CT.\",\n      \"Biopsy confirmed Embryonal rhabdomyosarcoma.\",\n      \"Recommendation for MDT discussion and treatment planning, standard for malignancy.\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"PAX-FOXO1 fusion negative - While this is a specific genetic marker often associated with certain types of rhabdomyosarcoma (like alveolar), its absence doesn't rule out malignancy, especially embryonal type.\"\n    ],\n    \"Alternative Explanations\": [\n      \"While the biopsy confirms rhabdomyosarcoma, the negative PAX-FOXO1 fusion might initially raise questions about specific subtypes, but it's consistent with embryonal rhabdomyosarcoma. Other non-malignant conditions causing parameningeal masses are unlikely given the biopsy result.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Conclusion\": \"YES, malignancy is confirmed. The report clearly states a diagnosis of Embryonal rhabdomyosarcoma based on biopsy results, supported by imaging findings of a parameningeal mass with intracranial extension and clinical suspicion.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 72,
      "timestamp": "2026-01-10T20:11:37.644919"
    },
    {
      "sample_idx": 73,
      "input": "03/12/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Physiological splenomegaly for age. No focal lesions. Normal echo texture. Benign finding. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 03/12/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": \"NO\",\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"No focal lesions identified on ultrasound.\",\n      \"Normal echo texture of the spleen.\",\n      \"Benign finding noted.\",\n      \"Explicit statement: 'No malignancy identified'.\",\n      \"Reassurance provided by the consultant.\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": [\n      \"Physiological splenomegaly for age (a normal variant).\"\n    ]\n  },\n  \"Final Diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 73,
      "timestamp": "2026-01-10T20:11:37.644937"
    },
    {
      "sample_idx": 74,
      "input": "11/10/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Ewing Sarcoma.\n\nFrom clinical notes: Ewing Sarcoma. Paediatric oncology assessment.\n\nFindings: permeative bone destruction in left femoral diaphysis with large soft tissue mass. Onion-skin periosteal reaction. EWSR1 fusion positive. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 11/10/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings SUPPORTING malignancy\": [\n      \"Palpable mass\",\n      \"Suspected Ewing Sarcoma\",\n      \"Ewing Sarcoma mentioned in clinical notes\",\n      \"Permeative bone destruction in left femoral diaphysis\",\n      \"Large soft tissue mass\",\n      \"Onion-skin periosteal reaction\",\n      \"EWSR1 fusion positive\"\n    ],\n    \"Findings CONTRADICTING malignancy\": [],\n    \"Alternative Explanations\": [\n      \"Infection (osteomyelitis) can cause bone destruction and soft tissue mass, but EWSR1 fusion positivity is highly specific for Ewing Sarcoma.\",\n      \"Benign bone tumor (e.g., osteoid osteoma, giant cell tumor) can present as a mass, but permeative destruction and onion-skin reaction are more typical of malignancy. EWSR1 fusion positivity rules out most benign tumors.\",\n      \"Metastatic disease (less likely in pediatric population without known primary, but possible). EWSR1 fusion positivity points specifically to Ewing Sarcoma.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Confirmed or Revised Diagnosis\": \"Malignancy confirmed. The findings strongly support a diagnosis of Ewing Sarcoma, particularly given the specific EWSR1 fusion positivity, permeative bone destruction, onion-skin periosteal reaction, and soft tissue mass in a pediatric patient.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 74,
      "timestamp": "2026-01-10T20:11:37.644974"
    },
    {
      "sample_idx": 75,
      "input": "28/12/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Reactive lymphadenopathy secondary to viral infection. Node size decreasing on follow-up. No atypical features. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 28/12/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"NO\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Screening request with no previous oncology history.\",\n      \"Findings explicitly state 'Reactive lymphadenopathy secondary to viral infection'.\",\n      \"Node size is decreasing on follow-up, suggesting a resolving inflammatory process.\",\n      \"No atypical features were noted.\",\n      \"The report explicitly states 'No malignancy identified'.\",\n      \"Reassurance was provided, implying a benign finding.\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": [\n      \"Reactive lymphadenopathy secondary to viral infection (as stated in the report).\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy?\": \"NO\",\n    \"Justification\": \"The report definitively concludes 'No malignancy identified' and attributes the findings to reactive lymphadenopathy secondary to a viral infection, further supported by decreasing node size on follow-up.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 75,
      "timestamp": "2026-01-10T20:11:37.645003"
    },
    {
      "sample_idx": 76,
      "input": "02/05/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Normal CBC with age-appropriate values. No blast cells. Platelets adequate. Hemoglobin within normal limits. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 02/05/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal CBC with age-appropriate values.\",\n      \"No blast cells identified in CBC.\",\n      \"Platelets adequate.\",\n      \"Hemoglobin within normal limits.\",\n      \"Explicit statement: 'No malignancy identified'.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"The report explicitly states 'Benign presentation' as the reason for request, suggesting the initial concern was non-malignant.\",\n      \"The report provides reassurance, further supporting a benign finding.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 76,
      "timestamp": "2026-01-10T20:11:37.645027"
    },
    {
      "sample_idx": 77,
      "input": "06/10/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Healing fracture - normal process. No pathological features. Bone density normal. Trauma history consistent. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 06/10/2025, 00:00",
      "response": "```json\n{\n  \"step1_initial_assessment\": \"NO\",\n  \"step2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Healing fracture - normal process.\",\n      \"No pathological features.\",\n      \"Bone density normal.\",\n      \"Trauma history consistent.\",\n      \"No malignancy identified.\",\n      \"Reassurance provided.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"The findings are consistent with a benign healing fracture following trauma.\"\n    ]\n  },\n  \"step3_final_diagnosis\": \"NO\"\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 77,
      "timestamp": "2026-01-10T20:11:37.645048"
    },
    {
      "sample_idx": 78,
      "input": "27/02/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Acute Lymphoblastic Leukemia.\n\nFrom clinical notes: Acute Lymphoblastic Leukemia. Paediatric oncology assessment.\n\nFindings: bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells. Immunophenotyping consistent with B-cell ALL. CNS involvement negative. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 27/02/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells.\",\n      \"Immunophenotyping consistent with B-cell ALL.\",\n      \"Clinical suspicion of Acute Lymphoblastic Leukemia (ALL).\"\n    ],\n    \"contradicting_findings\": [\n      \"CNS involvement negative.\"\n    ],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest ALL, other hematological malignancies could present with bone marrow infiltration, although the immunophenotyping points specifically to B-cell ALL. The negative CNS involvement is a specific finding regarding disease spread, not an alternative diagnosis for the primary condition.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_diagnosis\": \"Acute Lymphoblastic Leukemia (ALL), B-cell type.\",\n    \"assessment_revision\": \"Initial assessment confirmed.\"\n  }\n}\n```\n\"\"\"\n```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Clinical suspicion of Acute Lymphoblastic Leukemia (ALL).\",\n      \"Bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells.\",\n      \"Immunophenotyping consistent with B-cell ALL.\"\n    ],\n    \"contradicting_findings\": [\n      \"CNS involvement negative.\"\n    ],\n    \"alternative_explanations\": [\n      \"The high percentage of lymphoblasts in the bone marrow is characteristic of leukemia. Immunophenotyping confirms the specific type (B-cell ALL). While other conditions can affect the bone marrow, the combination of findings strongly points to ALL. The negative CNS involvement indicates the absence of detectable disease spread to the central nervous system at this time, but does not contradict the diagnosis of ALL itself.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_diagnosis\": \"Acute Lymphoblastic Leukemia (ALL), B-cell type.\",\n    \"assessment_revision\": \"Initial assessment confirmed.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 78,
      "timestamp": "2026-01-10T20:11:37.645074"
    },
    {
      "sample_idx": 79,
      "input": "17/05/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Post-viral lymphocytosis. Atypical lymphocytes resolving. Monospot positive. EBV serology confirms. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 17/05/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy\": \"NO\"\n  },\n  \"Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [],\n    \"Findings Contradicting Malignancy\": [\n      \"No malignancy identified.\",\n      \"Post-viral lymphocytosis.\",\n      \"Atypical lymphocytes resolving.\",\n      \"Monospot positive.\",\n      \"EBV serology confirms.\",\n      \"Reassurance provided.\"\n    ],\n    \"Alternative Explanations\": [\n      \"Infectious Mononucleosis (EBV infection)\",\n      \"Post-viral reactive process\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy\": \"NO\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 79,
      "timestamp": "2026-01-10T20:11:37.645098"
    },
    {
      "sample_idx": 80,
      "input": "18/02/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Physiological splenomegaly for age. No focal lesions. Normal echo texture. Benign finding. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 18/02/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"malignancy_present\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"Benign presentation\",\n      \"No previous oncology history\",\n      \"No focal lesions\",\n      \"No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"alternative_explanations\": [\n      \"Physiological splenomegaly for age (benign finding)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"malignancy_present\": \"NO\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and describes the findings as 'Benign'. The patient has a benign presentation and no prior oncology history. The splenomegaly is noted as physiological for age, further supporting a benign process.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 80,
      "timestamp": "2026-01-10T20:11:37.645119"
    },
    {
      "sample_idx": 81,
      "input": "11/06/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Benign soft tissue mass - lipoma confirmed. Well-circumscribed. No enhancement. No intervention required. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 11/06/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"malignancy_present\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Benign soft tissue mass - lipoma confirmed.\",\n      \"Well-circumscribed.\",\n      \"No enhancement.\",\n      \"No malignancy identified.\",\n      \"Reassurance provided.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign soft tissue mass (lipoma)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"malignancy_present\": \"NO\",\n    \"diagnosis\": \"Benign lipoma of soft tissue\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 81,
      "timestamp": "2026-01-10T20:11:37.645140"
    },
    {
      "sample_idx": 82,
      "input": "27/12/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 27/12/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Abnormal imaging\",\n      \"Suspected Wilms Tumor\",\n      \"Clinical notes mention Wilms Tumor\",\n      \"Large heterogeneous left renal mass with pseudocapsule\",\n      \"Favorable histology on biopsy\",\n      \"Stage II diagnosis\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"No vascular invasion\"\n    ],\n    \"Alternative Explanations\": [\n      \"While the findings strongly suggest Wilms Tumor, other renal masses in children exist, though less likely given the specific description and clinical suspicion. However, the report explicitly states 'Wilms Tumor' and 'Favorable histology on biopsy', making alternatives less probable.\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy?\": \"YES\",\n    \"Diagnosis\": \"Wilms Tumor, Stage II, Favorable Histology\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 82,
      "timestamp": "2026-01-10T20:11:37.645166"
    },
    {
      "sample_idx": 83,
      "input": "05/11/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Osteosarcoma.\n\nFrom clinical notes: Osteosarcoma. Paediatric oncology assessment.\n\nFindings: destructive lesion in distal femur with soft tissue component. Sunburst periosteal reaction. Elevated alkaline phosphatase. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 05/11/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Palpable mass\",\n      \"Suspected Osteosarcoma\",\n      \"Clinical notes mention Osteosarcoma\",\n      \"Destructive lesion in distal femur with soft tissue component\",\n      \"Sunburst periosteal reaction\",\n      \"Elevated alkaline phosphatase\",\n      \"Recommendation for MDT discussion and treatment planning (typical for malignancy)\"\n    ],\n    \"contradicting_findings\": [\n      \"None explicitly stated in the report\"\n    ],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest Osteosarcoma, other bone malignancies (e.g., Ewing sarcoma) or even aggressive benign lesions could potentially present similarly, although less likely given the combination of findings.\",\n      \"Infection (osteomyelitis) can sometimes cause destructive lesions, but the 'sunburst periosteal reaction' is more characteristic of malignancy, particularly osteosarcoma.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"YES\",\n    \"justification\": \"The combination of a palpable mass, suspected and noted diagnosis of Osteosarcoma, a destructive bone lesion with a soft tissue component, a characteristic 'sunburst periosteal reaction', and elevated alkaline phosphatase strongly indicates a malignant bone tumor, consistent with Osteosarcoma. While other possibilities exist, the evidence overwhelmingly supports malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 83,
      "timestamp": "2026-01-10T20:11:37.645199"
    },
    {
      "sample_idx": 84,
      "input": "23/11/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Healing fracture - normal process. No pathological features. Bone density normal. Trauma history consistent. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 23/11/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Benign presentation\",\n      \"No previous oncology history\",\n      \"Healing fracture - normal process\",\n      \"No pathological features\",\n      \"Bone density normal\",\n      \"Trauma history consistent\",\n      \"No malignancy identified\",\n      \"Reassurance provided\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Healing fracture due to trauma\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 84,
      "timestamp": "2026-01-10T20:11:37.645220"
    },
    {
      "sample_idx": 85,
      "input": "14/05/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Normal chest radiograph. Clear lung fields. No mediastinal mass. Heart size normal. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 14/05/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal chest radiograph\",\n      \"Clear lung fields\",\n      \"No mediastinal mass\",\n      \"Heart size normal\",\n      \"Explicit statement: 'No malignancy identified'\",\n      \"Reassurance provided\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Routine surveillance (implies no current symptoms or suspicion)\",\n      \"Patient is paediatric (context from oncologist's title, although not directly related to findings)\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 85,
      "timestamp": "2026-01-10T20:11:37.645239"
    },
    {
      "sample_idx": 86,
      "input": "11/06/2025, 00:00, PET-CT\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Hepatoblastoma.\n\nFrom clinical notes: Hepatoblastoma. Paediatric oncology assessment.\n\nFindings: large heterogeneous hepatic mass with elevated AFP. Fetal histology subtype. PRETEXT stage II. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 11/06/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Pancytopenia (can be associated with malignancy)\",\n      \"Suspected Hepatoblastoma (explicit suspicion)\",\n      \"Clinical notes: Hepatoblastoma (explicit mention)\",\n      \"Findings: large heterogeneous hepatic mass (highly suspicious for tumor)\",\n      \"Findings: elevated AFP (tumor marker associated with Hepatoblastoma)\",\n      \"Findings: Fetal histology subtype (specific subtype of Hepatoblastoma)\",\n      \"Findings: PRETEXT stage II (staging system for Hepatoblastoma)\",\n      \"Recommendation: MDT discussion and treatment planning (standard for malignancy)\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign liver tumor (less likely given AFP, histology, and staging)\",\n      \"Metastatic disease to the liver (less likely given primary suspicion of Hepatoblastoma)\",\n      \"Inflammatory or infectious process (less likely given mass characteristics and AFP)\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"YES\",\n    \"reasoning\": \"The report explicitly mentions 'Hepatoblastoma' in both the reason for request and clinical notes. The findings of a large heterogeneous hepatic mass, elevated AFP, specific fetal histology subtype, and PRETEXT staging strongly support the diagnosis of Hepatoblastoma, a malignant liver tumor common in children. While alternative explanations exist, they are less likely given the comprehensive evidence presented.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 86,
      "timestamp": "2026-01-10T20:11:37.645275"
    },
    {
      "sample_idx": 87,
      "input": "16/12/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Abnormal imaging. Suspected Acute Myeloid Leukemia.\n\nFrom clinical notes: Acute Myeloid Leukemia. Paediatric oncology assessment.\n\nFindings: myeloblasts accounting for 70% of marrow cellularity. Cytogenetic analysis reveals t(8;21) translocation. Favorable risk category. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 16/12/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Clinical suspicion of Acute Myeloid Leukemia (AML) noted in case history and clinical notes.\",\n      \"Bone marrow findings show myeloblasts accounting for 70% of marrow cellularity. A blast count of 20% or more in the bone marrow is diagnostic for acute leukemia.\",\n      \"Cytogenetic analysis reveals t(8;21) translocation, a specific genetic abnormality strongly associated with AML.\"\n    ],\n    \"Contradicting Findings\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"Alternative Explanations\": [\n      \"While the findings strongly point to AML, other conditions causing high blast counts (e.g., myelodysplastic syndromes with blast excess) are technically possible but less likely given the specific t(8;21) translocation which is characteristic of AML.\"\n    ]\n  },\n  \"Final Diagnosis\": {\n    \"Conclusion\": \"YES, malignancy is present. The findings are highly consistent with Acute Myeloid Leukemia (AML), specifically a subtype associated with the t(8;21) translocation, classified as favorable risk.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 87,
      "timestamp": "2026-01-10T20:11:37.645310"
    },
    {
      "sample_idx": 88,
      "input": "29/05/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Wilms Tumor.\n\nFrom clinical notes: Wilms Tumor. Paediatric oncology assessment.\n\nFindings: large heterogeneous left renal mass with pseudocapsule. No vascular invasion. Favorable histology on biopsy. Stage II. Recommend MDT discussion and treatment planning.\n\nDr James Chen, Consultant Paediatric Oncologist 29/05/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Suspected Wilms Tumor\",\n      \"Wilms Tumor mentioned in clinical notes\",\n      \"Large heterogeneous left renal mass with pseudocapsule found\",\n      \"Favorable histology on biopsy\",\n      \"Stage II classification\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Pancytopenia could be related to other conditions, but the context points towards Wilms Tumor.\",\n      \"While a large renal mass is found, other benign renal tumors exist, but the histology suggests malignancy.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"confirmed_malignancy\": \"YES\",\n    \"diagnosis_details\": \"Wilms Tumor, Stage II, favorable histology.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 88,
      "timestamp": "2026-01-10T20:11:37.645332"
    },
    {
      "sample_idx": 89,
      "input": "16/01/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Acute Lymphoblastic Leukemia.\n\nFrom clinical notes: Acute Lymphoblastic Leukemia. Paediatric oncology assessment.\n\nFindings: bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells. Immunophenotyping consistent with B-cell ALL. CNS involvement negative. Recommend MDT discussion and treatment planning.\n\nDr James Chen, Consultant Paediatric Oncologist 16/01/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"YES\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Bone marrow infiltration with lymphoblasts comprising 85% of nucleated cells.\",\n      \"Immunophenotyping consistent with B-cell ALL.\",\n      \"Clinical suspicion of Acute Lymphoblastic Leukemia (ALL) based on palpable mass and paediatric oncology assessment.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"While the findings strongly suggest ALL, other haematological malignancies or reactive processes with atypical lymphoid proliferation could be considered, although the high percentage of lymphoblasts and specific immunophenotyping make these less likely.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"YES\",\n    \"diagnosis\": \"Acute Lymphoblastic Leukemia (ALL), B-cell lineage\",\n    \"justification\": \"The report explicitly states bone marrow infiltration with 85% lymphoblasts, consistent with immunophenotyping for B-cell ALL. This meets the diagnostic criteria for ALL. The clinical suspicion and paediatric context further support this diagnosis.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 89,
      "timestamp": "2026-01-10T20:11:37.645361"
    },
    {
      "sample_idx": 90,
      "input": "06/09/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Retinoblastoma.\n\nFrom clinical notes: Retinoblastoma. Paediatric oncology assessment.\n\nFindings: intraocular mass with calcifications. Bilateral disease. Family history positive. RB1 germline mutation detected. Recommend MDT discussion and treatment planning.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 06/09/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Palpable mass\",\n      \"Suspected Retinoblastoma\",\n      \"Clinical notes confirm Retinoblastoma\",\n      \"Intraocular mass with calcifications\",\n      \"Bilateral disease\",\n      \"Family history positive\",\n      \"RB1 germline mutation detected\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": []\n  },\n  \"Final Diagnosis\": {\n    \"Is there malignancy\": \"YES\",\n    \"Diagnosis\": \"Retinoblastoma\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 90,
      "timestamp": "2026-01-10T20:11:37.645381"
    },
    {
      "sample_idx": 91,
      "input": "30/01/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Benign presentation. No previous oncology history.\n\nFindings: Healing fracture - normal process. No pathological features. Bone density normal. Trauma history consistent. No malignancy identified. Reassurance provided.\n\nDr Rachel Patel, Consultant Paediatric Oncologist 30/01/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"malignancy_present\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [\n      \"Reason for Request: Benign presentation.\",\n      \"No previous oncology history.\",\n      \"Findings: Healing fracture - normal process.\",\n      \"No pathological features.\",\n      \"No malignancy identified.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Healing fracture due to trauma.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"malignancy_present\": \"NO\",\n    \"diagnosis\": \"Healing fracture, benign process. No evidence of malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 91,
      "timestamp": "2026-01-10T20:11:37.645402"
    },
    {
      "sample_idx": 92,
      "input": "22/05/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Routine surveillance. No previous oncology history.\n\nFindings: Benign bone cyst - resolved. No aggressive features. Normal bone density. No recurrence on imaging. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 22/05/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"No malignancy identified.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Benign bone cyst - resolved.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"conclusion\": \"NO malignancy identified. The patient's previous benign bone cyst has resolved, and there is no evidence of malignancy on the bone marrow biopsy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 92,
      "timestamp": "2026-01-10T20:11:37.645420"
    },
    {
      "sample_idx": 93,
      "input": "04/02/2025, 00:00, BONE MARROW BIOPSY\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Healing fracture - normal process. No pathological features. Bone density normal. Trauma history consistent. No malignancy identified. Reassurance provided.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 04/02/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": \"NO\",\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"No malignancy identified.\",\n      \"No pathological features.\",\n      \"Healing fracture - normal process.\"\n    ],\n    \"alternative_explanations\": [\n      \"Trauma history consistent with healing fracture.\",\n      \"Normal bone density.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": \"NO\"\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 93,
      "timestamp": "2026-01-10T20:11:37.645437"
    },
    {
      "sample_idx": 94,
      "input": "05/08/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Rule out malignancy. No previous oncology history.\n\nFindings: Normal brain MRI for age. No mass lesion. No abnormal enhancement. Headaches attributed to migraine. No malignancy identified. Reassurance provided.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 05/08/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal brain MRI for age.\",\n      \"No mass lesion identified.\",\n      \"No abnormal enhancement observed.\",\n      \"Explicit statement: 'No malignancy identified.'\",\n      \"Reassurance provided to the patient.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"Headaches attributed to migraine.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"diagnosis\": \"No malignancy identified.\",\n    \"reasoning\": \"The report explicitly states 'No malignancy identified' and details findings consistent with a normal brain MRI (no mass lesion, no abnormal enhancement). The headaches are attributed to migraines, providing an alternative explanation for the presenting symptom.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 94,
      "timestamp": "2026-01-10T20:11:37.645463"
    },
    {
      "sample_idx": 95,
      "input": "10/03/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Screening. No previous oncology history.\n\nFindings: Healing fracture - normal process. No pathological features. Bone density normal. Trauma history consistent. No malignancy identified. Reassurance provided.\n\nDr Emma Wilson, Consultant Paediatric Oncologist 10/03/2025, 00:00",
      "response": "```json\n{\n  \"initial_assessment\": {\n    \"is_malignancy\": \"NO\"\n  },\n  \"evidence_collection\": {\n    \"supporting_findings\": [],\n    \"contradicting_findings\": [\n      \"No malignancy identified.\",\n      \"No pathological features.\",\n      \"Healing fracture - normal process.\",\n      \"Trauma history consistent.\"\n    ],\n    \"alternative_explanations\": [\n      \"Healing fracture due to trauma.\"\n    ]\n  },\n  \"final_diagnosis\": {\n    \"is_malignancy\": \"NO\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 95,
      "timestamp": "2026-01-10T20:11:37.645480"
    },
    {
      "sample_idx": 96,
      "input": "28/09/2025, 00:00, ULTRASOUND\n\nCase History:\n\nReason for Request: Palpable mass. Suspected Hodgkin Lymphoma.\n\nFrom clinical notes: Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: mediastinal lymphadenopathy with bulky anterior mediastinal mass. PET-CT showing FDG-avid nodes. Classical Hodgkin, nodular sclerosing type. Recommend MDT discussion and treatment planning.\n\nDr Michael Taylor, Consultant Paediatric Oncologist 28/09/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Palpable mass noted clinically.\",\n      \"Suspected Hodgkin Lymphoma mentioned in the reason for request.\",\n      \"Clinical notes explicitly state Hodgkin Lymphoma.\",\n      \"Ultrasound findings: mediastinal lymphadenopathy with bulky anterior mediastinal mass.\",\n      \"PET-CT findings: FDG-avid nodes (suggestive of metabolic activity often seen in malignancy).\",\n      \"Histological classification: Classical Hodgkin, nodular sclerosing type (confirms lymphoma subtype).\"\n    ],\n    \"Contradicting Findings\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"Alternative Explanations\": [\n      \"While the report strongly points to Hodgkin Lymphoma, other causes of mediastinal masses and lymphadenopathy (e.g., infections like tuberculosis, other lymphomas, thymoma, germ cell tumors) should theoretically be considered, although the clinical suspicion and specific histological type make Hodgkin Lymphoma the most likely diagnosis.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Conclusion\": \"The diagnosis of Hodgkin Lymphoma, specifically Classical Hodgkin, nodular sclerosing type, is confirmed based on clinical suspicion, imaging findings (ultrasound, PET-CT), and histological classification. The report strongly supports the presence of malignancy.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 96,
      "timestamp": "2026-01-10T20:11:37.645516"
    },
    {
      "sample_idx": 97,
      "input": "02/01/2025, 00:00, X-RAY\n\nCase History:\n\nReason for Request: Bone pain. Suspected Brain Tumor - Glioma.\n\nFrom clinical notes: Brain Tumor - Glioma. Paediatric oncology assessment.\n\nFindings: left temporal lobe infiltrative mass with mass effect. FLAIR hyperintensity. Biopsy confirms diffuse astrocytoma WHO grade II. Recommend MDT discussion and treatment planning.\n\nDr Sophie Richardson, Consultant Paediatric Oncologist 02/01/2025, 00:00",
      "response": "```json\n{\n  \"Step 1 - Initial Diagnosis\": {\n    \"Initial Assessment\": \"YES\"\n  },\n  \"Step 2 - Evidence Collection\": {\n    \"Findings Supporting Malignancy\": [\n      \"Clinical suspicion of Brain Tumor - Glioma.\",\n      \"Imaging (X-RAY - although MRI/CT would be typical for brain tumors) shows 'left temporal lobe infiltrative mass with mass effect'.\",\n      \"FLAIR hyperintensity on imaging suggests abnormality.\",\n      \"Biopsy confirms 'diffuse astrocytoma WHO grade II'.\"\n    ],\n    \"Findings Contradicting Malignancy\": [\n      \"None explicitly stated in the report.\"\n    ],\n    \"Alternative Explanations\": [\n      \"While the report confirms a diagnosis, the term 'infiltrative mass' could potentially describe other conditions, but the biopsy result strongly points towards malignancy.\",\n      \"The mention of 'X-RAY' for a suspected brain tumor is unusual; MRI or CT are standard. This might be a data entry error or refer to a different study not detailed here, but it doesn't contradict the core findings.\"\n    ]\n  },\n  \"Step 3 - Final Diagnosis\": {\n    \"Final Assessment\": \"YES, the report confirms a diagnosis of diffuse astrocytoma WHO grade II, which is a type of malignant brain tumor.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 97,
      "timestamp": "2026-01-10T20:11:37.645547"
    },
    {
      "sample_idx": 98,
      "input": "29/06/2025, 00:00, MRI BRAIN\n\nCase History:\n\nReason for Request: Follow-up post-treatment. No previous oncology history.\n\nFindings: Normal CBC with age-appropriate values. No blast cells. Platelets adequate. Hemoglobin within normal limits. No malignancy identified. Reassurance provided.\n\nDr James Chen, Consultant Paediatric Oncologist 29/06/2025, 00:00",
      "response": "```json\n{\n  \"step_1_initial_assessment\": {\n    \"is_malignancy_present\": \"NO\"\n  },\n  \"step_2_evidence_collection\": {\n    \"supporting_findings\": [\n      \"Normal CBC with age-appropriate values.\",\n      \"No blast cells identified.\",\n      \"Platelets adequate.\",\n      \"Hemoglobin within normal limits.\",\n      \"Explicit statement: 'No malignancy identified.'\",\n      \"Reassurance provided to the patient.\"\n    ],\n    \"contradicting_findings\": [],\n    \"alternative_explanations\": [\n      \"The patient is undergoing follow-up post-treatment for a condition *other* than malignancy (e.g., infection, inflammation, benign lesion).\",\n      \"The patient had a previous concern for malignancy that has been ruled out.\",\n      \"The report is documenting a routine follow-up with no current suspicion of malignancy.\"\n    ]\n  },\n  \"step_3_final_diagnosis\": {\n    \"final_assessment\": \"NO\",\n    \"justification\": \"The report explicitly states 'No malignancy identified' and provides supporting laboratory findings (Normal CBC, no blast cells, adequate platelets, normal hemoglobin). The context is a follow-up post-treatment, but the report itself does not indicate the treatment was for malignancy. Therefore, based on the provided information, malignancy is not currently identified.\"\n  }\n}\n```\n",
      "predicted": false,
      "ground_truth": false,
      "correct": true,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 98,
      "timestamp": "2026-01-10T20:11:37.645579"
    },
    {
      "sample_idx": 99,
      "input": "21/03/2025, 00:00, CT CHEST/ABDOMEN\n\nCase History:\n\nReason for Request: Pancytopenia. Suspected Hodgkin Lymphoma.\n\nFrom clinical notes: Hodgkin Lymphoma. Paediatric oncology assessment.\n\nFindings: mediastinal lymphadenopathy with bulky anterior mediastinal mass. PET-CT showing FDG-avid nodes. Classical Hodgkin, nodular sclerosing type. Recommend MDT discussion and treatment planning.\n\nDr Sarah Mitchell, Consultant Paediatric Oncologist 21/03/2025, 00:00",
      "response": "```json\n{\n  \"Initial Assessment\": {\n    \"Is there malignancy?\": \"YES\"\n  },\n  \"Evidence Collection\": {\n    \"Supporting Findings\": [\n      \"Suspected Hodgkin Lymphoma in clinical notes.\",\n      \"Mediastinal lymphadenopathy with bulky anterior mediastinal mass.\",\n      \"FDG-avid nodes on PET-CT.\",\n      \"Classical Hodgkin, nodular sclerosing type confirmed.\",\n      \"Recommendation for MDT discussion and treatment planning.\"\n    ],\n    \"Contradicting Findings\": [],\n    \"Alternative Explanations\": []\n  },\n  \"Final Diagnosis\": {\n    \"Conclusion\": \"YES, the report confirms the presence of Classical Hodgkin Lymphoma, nodular sclerosing type, based on clinical suspicion, imaging findings (mediastinal mass, FDG-avid nodes), and histological classification.\"\n  }\n}\n```",
      "predicted": false,
      "ground_truth": true,
      "correct": false,
      "reasoning": "",
      "findings": [],
      "fracture_mentioned": null,
      "idx": 99,
      "timestamp": "2026-01-10T20:11:37.645605"
    }
  ],
  "end_time": "2026-01-10T20:11:37.646021",
  "duration_seconds": 88.900689
}